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Traditional animal models of severe asthma do not recapitulate defining asthma
characteristics, including persistent airway hyper-responsiveness, and chronic
neutrophilic inflammation. This is problematic because moderating airway hyperresponsiveness decreases asthma frequency and severity, making it a paramount
pharmacological goal in asthma research. Employing a spontaneous equine asthma model
(equine pasture asthma, EPA), we first confirmed reversible airway obstruction in eight
diseased horses during asthma exacerbations in response to ß2-adrenergic agonist
stimulation. Next, non-specific airway hyper-responsiveness was confirmed using
methacholine bronchoprovocation to identify the provocative concentration causing a
40% increase in baseline lung resistance (PC40RL)- a threshold similarly employed in
evaluating human asthmatics unable to mount forced expiration. The PC40RL of ten EPA
horses was consistently <1mg/ml of methacholine, which is a cutoff that has been used to
diagnose severe human asthma. Like non-asthmatic humans, ten control horses did not

respond to methacholine doses up to 16 mg/ml. Finally, persistence of AHR was
documented during absence of seasonal aeroallergen triggers in five horses that were
evaluated between 3 and 31 months following the initial methacholine
bronchoprovocation.
This unique ability of EPA horses to model AHR attributes that are not addressed
by other animal models points to the suitability of EPA horses to decipher the
mechanistic basis of airway hyper-responsiveness. Building on knowledge that

2-

adrenergic receptor (AR) signaling is required to develop the asthma phenotype in a
murine model, differentially expressed genes from serial lung biopsies of two EPA
affected and two controls were filtered to identify genes that interact with the

2-AR.

Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 4 (HCN4) was
prioritized because of its interactions with the

2-AR.

Relative to control horses, HCN4

was constitutively expressed in airway smooth muscle of EPA horses during remission
and increased during seasonal disease exacerbation. Agonism of airway contraction by
HCN4 was proven using the specific HCN4 antagonist, ivabradine, which caused dose
dependent decreases in carbachol induced contractile responses in both EPA and control
bronchi in vitro. These findings highlight utility of EPA as a model of severe asthma and
HCN4 as a mediator of airway contraction that warrants further investigation in severe
human asthma.
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CHAPTER I
LITERATURE REVIEW
Introduction
Asthma is a chronic respiratory disease affecting 7.1 million children and 18.9 million
adults throughout the United States (1). It is characterized by cyclic bouts of airway
obstruction, with persistent airway hyper-responsiveness (AHR) and airway
inflammation (2). “Asthma” is a Greek word meaning “short of breath” (3). The first
written account of asthma is in Homer’s Iliad that refers to a warrior who died following
a battle with “asthma and perspiration” (4). The first time the term “asthma” appeared
medically was during the time of Hippocrates (460-360 B.C.) (4). In the early 19th
century, Henry Hyde Salter defined asthma as a “paroxysmal dyspnoea of a peculiar
character, generally periodic with intervals and healthy respiration between the attacks,”
in his publication “On Asthma: Its Pathology and Treatment”(5). Despite its long
history and world-wide prevalence, understanding of the pathophysiologic basis of
asthma is incomplete.
This dissertation focuses on a naturally occurring animal model of asthma, Equine
Pasture Asthma (EPA), and establishes its translational relevance to severe adult
neutrophilic asthma. Building on shared clinical and pathologic features of EPA and
severe human asthma previously documented by our laboratory (6, 7), the present work
first demonstrates that airway hyper-responsiveness (AHR) is a hallmark of EPA,
1

confirming EPA’s homology with a key diagnostic criterion of severe human asthma.
Then, building on the strong translational unity of EPA and severe human asthma, a selfcontrolled transcriptomics approach was employed to identify a novel mechanistic basis
of AHR. We hypothesize that this mechanistic basis of AHR is relevant to AHR in severe
human asthma and demonstrate that alternate use of an approved human therapeutic agent
moderates AHR in the EPA model.
Equine Pasture Asthma (EPA)
EPA is an inflammatory small airway disease that is a part of the broader range of
respiratory conditions now termed “equine asthma” (8). Equine asthma ranges from
a mild-moderate condition, previously referred to as inflammatory airway disease
(IAD), to a severe condition, which is referred to as severe equine asthma (SEA) that
includes a pasture associated form (EPA) and an indoor or barn associated form
“barn-dust asthma” (BDA), previously referred to as Recurrent Airway Obstruction
or RAO) (8). The term equine asthma has only recently been adopted, despite the
fact that these conditions have been described for several decades. Over time these
conditions affecting the airways of horses have been referred to by different names.
For instance, BDA has been previously referred to as Recurrent Airway Obstruction
or (RAO), heaves, and equine chronic obstructive pulmonary disease (COPD) (8).
Similarly, EPA has been previously referred to as summer-pasture associated RAO
(SPARAO) and summer-pasture associated obstructive pulmonary disease
(SPAOPD) (9, 10). The change in nomenclature over the years has been in efforts to
avoid comparisons with similar, yet different human diseases. For example, the
2

term ‘chronic obstructive pulmonary disease’ or ‘COPD’ was commonly used to
name equine conditions during the 1980s and 1990s, but this was discontinued to
acknowledge the many differences from the human COPD, for instance, emphysema
is not a component of the equine conditions, but it is a hallmark of human COPD.
Due to recent changes in the equine nomenclature to characterize the disease more
appropriately, EPA will be used for the duration of this work.
BDA has been estimated to affect roughly 14% of horses housed in temperate
climates (11). It is a disease of mature, often middle aged, horses that have been
found to be responsive to bronchodilators or a change in environment (12). EPA is
typically seen in horses seven years of age and older. Both BDA and EPA share
many similarities with respect of clinical signs, which are characterized by coughing,
reluctance to exercise, labored breathing, and wheezing. These signs improve in
response to bronchodilators and decreasing environmental antigen exposure (8,
13). In contrast, mild-moderate equine asthma affects younger horses, and is
characterized by horses that appear clinically normal at rest, but exhibit exercise
intolerance and exercise induced coughing. (8).
Unlike the similar phenotype of BDA, EPA is associated with a history of exposure
to increased fungi and pollen counts while being kept on pasture during months of
increased ambient temperature (9, 10, 13). BDA (also previously called COPD or
‘heaves’) is triggered by inhalation of dust particles and molds while in barns,
especially particles associated with feeding moldy hay (14–16). The change in
nomenclature over the years has been in efforts to avoid comparisons with similar,
yet different human diseases. For example, the term ‘chronic obstructive pulmonary
3

disease’ or ‘COPD’ was commonly used to name these conditions in the 1980s and
1990s, but was discontinued to acknowledge the differences (i.e. causes, variations
in severity, and clinical presentation) between the human disease of the same name
when compared to the equine disease (12, 14). In COPD the airway obstruction is
not reversible while asthma is specifically defined as a condition in which airway
obstruction is reversible. Generally, the previously mentioned conditions
characterizing EPA are observed in the summer months, hence the previous
nomenclature of EPA, summer pasture associated recurrent airway obstruction
(SPARAO). However, due to recent changes in the equine nomenclature to
characterize the disease more appropriately, EPA will be used for the duration of
this work.
Unlike BDA, which is a disease associated with domestication (14), EPA is caused
by antigens that are naturally occurring in the horse’s environment. EPA is
spontaneous and naturally occurring in a region of the United States seeing a steady
increase in asthma prevalence (i.e. Mississippi, Alabama, Tennessee) (17) and in the
state of Mississippi which the capital (Jackson, MS) has recently been named
number one for spring allergies (18). The following sections discuss specific aspects
of EPA, make comparisons between EPA and the barn-dust form of equine asthma,
and also highlight similarities between these two equine diseases and human
asthma.

4

Diagnosis of EPA
Diagnosis of EPA begins with a thorough history of the patient’s clinical signs.
Affected horses are adults, usually over seven years or age, that are housed on pasture
when signs are noted (13, 19). No breed or sex predilection has been identified (20, 21).
Owners may note an improvement in clinical signs when the animal is taken off pasture
and moved into a barn, which is attributed to a decreased exposure to the inciting
environmental triggers. By contrast, animals affected with BDA have historically been
kept indoors, where they are exposed to barn dust and various hay molds.
Signs noted by owners may include coughing, increased respiratory effort and
respiratory rate (tachypnea), exercise intolerance, nasal discharge, and nostril flare (13,
22). Physical exam findings may include increased lung sounds and wheezes, which are
classically end expiratory, an increased contraction of the external abdominal oblique
muscles (known as a ‘heave line’), and increased tracheal sounds. Increased respiratory
effort, as determined by the formula (medial nostril flare score + lateral nostril flare
score)/2 + abdominal lift score, has been demonstrated to correlate to increased
intrathoracic pressures (i.e. maximal change in pleural pressure, ΔPplmax) that drive
respiration (22, 23). Cytology results in SEA, often from bronchoalveolar lavage fluid
(BALF), must include a predominance and increase in neutrophils above normal cell
counts (22). Cytologic findings of horses with mild-moderate asthma, by contrast, are
mildly neutrophilic and have monocytosis and lymphocytosis (24).
If the patient is compliant, non-specific bronchoprovocation testing may be performed
for a definitive diagnosis (25). In this testing, horses are exposed to a non-specific
airway irritant, most commonly methacholine or histamine, in order to identify increased
5

sensitivity that is characterized by airway constriction in response to irritant doses that do
not cause airway constriction in normal horses. Increase in maximum pleural pressure
(ΔPplmax), increase in lung resistance (RL), and decrease in dynamic compliance (Cdyn) of
the lung occur in affected horses in response to serially increasing doses of irritant (24).
Horses affected with EPA should be hyper-responsive to inhaled constricting agents
compared with clinically normal horses (7). In humans with asthma, bronchoprovocation
is not performed in patients with less then 30% of their predicted expiratory volume (27)
and should also not be performed in horses experiencing clinical asthma exacerbation. In
such cases, conventional pulmonary function testing has been shown to yield ΔPplmax >6
mm Hg (25).
Finally, EPA affected horses respond well to removal from the inciting agents in
pasture. Once stalled, these horses generally show marked respiratory improvement.
Bronchodilators of the ß2-adrenergic receptor agonist class of therapeutics (i.e. β2-AR
agonists: albuterol, levalbuterol) are typically used to initially reverse airway obstruction.
Buscapam, a parsympatholytic agent, has also been demonstrated to effect
bronchodilation in horses with SEA (28). The reversibility of airway obstruction (ie
bronchodilation) in response to therapeutic intervention is a key criterion for asthma
diagnosis. (29, 30). In addition to clinical improvement in dyspnea as evidence of
bronchodilation, reversibility can also be documented using conventional pulmonary
mechanics with decreases in ΔPplmax and RL accompanied by an increase in Cdyn being
indicative of a bronchodilatory response to therapy. Oxygen insufflation may be needed
in cases of prolonged hypoxemia (7). In the barn dust form of disease, soaking hay helps
to reduce the effect of mold exacerbating disease. Many times, a decrease of clinical
6

signs following removal from pasture or from hay and bedding, is a good diagnostic
indicator of the reversible airway obstruction component of disease (31).
Airway hyper-responsiveness in SEA
Airway hyper-responsiveness (AHR) is a state in which airways react to an
airway spasmogen to a higher degree than they normally should. AHR was first
associated with asthma by Dr. Szentivanyi in 1968, who suspected an association with an
abnormality in the -adrenergic system (32, 33). In asthma, AHR is characterized by
persistence at a baseline level. While the etiology of this persistence is incompletely
characterized, airway smooth muscle (ASM) from asthmatics has been demonstrated to
be hyper-contractile, even in the absence of inflammation in primary cell culture (34–36).
Lessons from in vitro models, which have been questioned because they do not
successfully recapitulate the persistence of AHR that is characteristic of the asthma
phenotype, have suggested roles for airway remodeling from chronic inflammation a well
as acute, variable AHR from episodes of inflammatory increases at times of antigen
exposure (37).
AHR is a key characteristic in the common respiratory conditions SEA and mildmoderate equine asthma (38). While ASM is considered to be the primary cell type
responsible for AHR (39), differences in ASM contractile function, cell migration,
proliferation, and secretion of pro-inflammatory cytokines from ASM cells have all been
suggested to play a role in AHR (40). Smooth muscle contraction from asthmatics is
greater than that of non-asthmatics (36). In human asthma, increase in contraction has
been suggested to be due to increased ASM mass (41), with the increased thickness
allowing increased tension forces. However, peripheral airway smooth muscle has also
7

been shown to have increased shortening velocity in horses with BDA relative to nondiseased controls, indicating that the phenomenon of increased contractility does not
require increased ASM mass (42). Earlier studies had questioned if this is a universal
truth, however (43). Still, greater increases in ASM have been associated with severity of
asthma (44). Increases in ASM have also been found in horses with BDA (45) and EPA
(6, 46).
The autonomic nervous system innervates airway smooth muscle. Through
parasympathetic input, postganglionic nerves release acetylcholine that stimulates
muscarinic receptors, leading to bronchoconstriction and mucus secretion. Cholinergic
M3 receptor signaling is considered the principal mode of neuronally mediated
bronchoconstriction in the human (47) and equine lung (48). Contraction of airway
smooth muscle (ASM) surrounding conducting airways in the asthmatic lung contributes
to shortness of breath that can be fatal. This contraction can also be induced by release of
histamine and cysteinal leukotrienes of mast cells and basophils (49), to which asthmatics
have been demonstrated to be hyper-responsive. In this investigation, responses to
inhaled allergens were compared between asthmatics and people with a similar severe
cutaneous immune response. Though both groups released similar amounts of histamines
and leukotrienes (bronchoconstrictors) in airways, only asthmatics demonstrated
exaggerated airway narrowing (49).
Inhibition of parasympathetic nervous system muscarinic receptor mediated
bronchoconstriction is provided by parasympathetic M2 receptor signaling and by postjunctional non-adrenergic non-cholinergic (NANC) nerves (50). The M2 receptor is the
most abundant in equine peripheral lung tissue (51). M2 muscarinic receptors on
8

parasympathetic nerves inhibit parasympathetic signaling by limiting further
acetylcholine release and thus provide a negative feedback that limits neurotransmission
and bronchoconstriction in diverse species (47, 52, 53). In addition, the M2 receptor can
also inhibit

2-AR

relaxation of ASM by inhibiting adenylate cyclase (54). Simultaneous

inhibition of both M2 and M3 receptors does not alter cholinergic activity in BDA
airways (55). Both M2 receptor dysfunction (56–58) and lack of normal inhibition
provided by non-adrenergic non-cholinergic (NANC) nerves at distal airways (31,32)
have been implicated in the pathogenesis of AHR in horses with BDA.
Sutcliffe et al. (34) found that oxidative stress of ASM in asthmatics contributes to the
degree of AHR. An overexpression of NOX4 in ASM of asthmatics has been suggested
to cause oxidative stress and consequently lead to airway hyper-contractility. Another
study found an increase in smooth muscle myosin light chain kinase (smMLCK) in the
bronchial smooth muscle of asthmatics (35), but this has not been a consistent finding
(36). Increased smMLCK would cause more bridging of myosin and actin chains (36).
This would cause a greater shortening as demonstrated in dogs (59) and humans (60).
The increased shortening would result in more luminal narrowing.
The heritability of AHR has been reported to be approximately 30% (61). In mice,
hyper-reactivity to acetylcholine and serotonin have been demonstrated to be inherited in
an autosomal recessive manner, with linkage analysis demonstrating that the associated
genes were not closely linked and indicating that AHR in mice is a polygenic trait (62,
63). Congruent with this complexity, another study of house dust mite sensitized mice
demonstrated epigenetically modulated transforming growth factor beta as associated
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with AHR (62). RNA from bronchial biopsy identified 4 genes not only associated with
asthma, but also with AHR: RPTOR, VANGL1, FAM129A, and LEPREL1 (64).
In summary AHR persists at a baseline level in human asthma. While the etiology of
this persistence is incompletely characterized, ASM from asthmatics has been
demonstrated to be hyper-contractile, even in the absence of inflammation in primary cell
culture (34–36). Lessons from in vitro models (which have been questioned because they
do not successfully recapitulate the persistence of AHR) have suggested roles for airway
remodeling. These include chronic inflammation as well as acute, variable AHR from
episodic increases in airway inflammation at times of antigen exposure (37). Seasonal
increases of AHR have been found in allergic asthmatics (65). However, caution must be
used when faced with a negative bronchial challenge (66). A negative challenge does not
exclude asthma but must be considered with the presence or absence of clinical signs.
Chapman and Irvin (66) suggest that in patients with a history of asthma-like signs, the
term “currently negative AHR” may be more appropriate. While clearly AHR is
complex, and the understanding of its pathogenesis is poorly refined, demonstrated
relationships between magnitude of AHR and asthma severity warrant focused research
efforts to decipher the mechanistic basis of AHR in order to moderate asthma.
Pulmonary Function Testing in Horses
Methods for pulmonary function testing that have been most employed in horses
include conventional pulmonary mechanics, open plethysmography, and oscillometry
(forced and impulse). Clinically, pulmonary function testing is indicated in equine
patients with non-responsive cough, abnormal chest auscultation, exercise intolerance,
increased mucus, and tachypnea that is not referrable to pneumonia (67). While these
10

tests reflect the magnitude of airway obstruction at the time of testing, a limit of such
testing is that isolated measurements of airway obstruction do not necessarily correlate to
longitudinal measures of asthma severity- including asthma frequency and the magnitude
of asthma attacks over protracted periods. In human asthma, strong correlations between
increasing sensitivity to bronchoprovocation with methacholine and longitudinal
measures of asthma frequency and severity of attacks have been identified, leading to the
common employment of methacholine bronchoprovocation in human asthma subjects in
order to gauge longitudinal measures of asthma severity (27).
Conventional pulmonary mechanics is the gold standard for diagnosing airway
obstruction in horses (9, 37, 41). Increases in intrapleural pressure were first identified in
horses with respiratory illness in the 1960s using conventional pulmonary mechanics
(68). Measurements of airway obstruction derived from conventional pulmonary
mechanics in horses typically focus on three parameters: maximum change in intrapleural
pressure ( Pplmax), total lung resistance (RL), and dynamic compliance (Cdyn) (35). These
measurements are calculated from input signals that quantify changes in intrapleural
pressure, air flow, and air volume, dynamically, throughout the breathing cycle.
Intrapleural pressure is derived from an esophageal balloon catheter that is placed via the
nose, into the thoracic esophagus. Air flow is measured using a pneumotachograph which
in horses is attached to an airtight mask that covers the horse’s muzzle. Volume is
derived from the integral of the flow signal.
The maximal change in intrapleural pressure ( Pplmax) refers to the difference in
intrapleural pressue between maximal inspiration and maximal expiration. Total lung
resistance (RL) reflects friction of air against airway walls (67) and is calculated by
11

dividing the change in transpulmonary pressure by the associated change in airflow
between isovolumetric points (69). Because the transpulmonary pressure (i.e.
atmospheric pressure-alveolar pressure) cannot be directly measured, the measured
intrapleural pressure difference serves as its surrogate. Cdyn is a measure of lung elastance
defined as the ratio of the tidal volume to the difference in intrapleural pressure between
zero airflow relating to beginning of inspiration and expiration (70). As airways constrict,
RL increases and Cdyn decreases. Cdyn can be affected by both obstruction and elasticity.
A drawback of conventional mechanics is its dependence on spontaneous respiratory
frequency which slows acquisition with low respiratory rates (35). Respiratory frequency
has been shown to impact RL in the dog model (42). However, conventional mechanics
provides the unparalleled advantage of directly measuring parameters of airway
obstruction.
Forced oscillometry (FOM) is a technique where the horse is exposed to sinusoidal,
external air flow, generated by compressed air, via a facemask (71). The external source
is intended to produce oscillations of pressure that are measured at the airway opening
(67). FOM has been proven to be a realiable test of lung function in the horse and has the
advantage of differentiating small airway contraction from that of larger airways (72, 73).
As a non-invasive technique, it is more appropriate for less compliant animals.
Another method of pulmonary function testing called open plethysmography has been
done in horses (74, 75). This method uses external sensors placed on the animal to take
measurements of dynamic changes in the thoracic circumference that are then correlated
to measurements of air flow (74, 76). In the horse, these measurements are made using
thoracic inductance bands that are attached to each horse along with a fitted mask and
12

pneumotachograph that measures changes in airflow at the nostril. Therefore changes in
flow at the airway opening and changes in body surface area are used to analyze
respiratory function (67). Changes in flow (

flow)

are used to find the PC (change in flow

signal found from the thoracic volume change at the peak of expiration) (74, 76). This
method has been shown to produce reproducible results for up to a year with caution if
ambient temperature is low (i.e. less than 5 C) (76). Plethysmography is also able to give
information on the breathing pattern through the thoracic bands (67). Plethysmography
may be closed (within a closed environment) or open. The open method is more suitable
for large animals since restraining a horse in a small, closed environment has safety
concerns. This method has been successfully combined with methacholine
bronchoprovocation to identify airway hyper-responsiveness in horses with mildmoderate asthma (ie IAD) (77).
Bronchoprovocation
The pulmonary function methods previously addressed can be combined with
bronchoprovocation to diagnose airway disease and to understand the mechanics of AHR.
The American Thoracic Society has established methacholine challenge guidelines for
diagnosing asthma that rely on giving set concentrations of an airway spasmogen to
measure reactivity (78). The two-minute tidal breathing protocol is one of the most
common bronchoprovocation methods. It involves administering doubling doses of
methacholine after baseline pulmonary parameters have been acquired. The guidelines
for testing adults and children differ, since children are considered “non-compliant” (79).
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For example, in children the dose of methacholine causing a 40% increase in RL from
baseline defines the study end-point (79) and asthma severity (Table 1) (27).
Typically either provocative dose (PD) or provocative concentration (PC) are used to
report study end-points. The PC or PD is the inhaled concentration or dose, respectively,
that is required to reach a set change from a baseline measurement (79). PC is typically
used for 2 minute tidal breathing methods, and PD is used for breath dosimeter methods
(78). The American Thoracic Society recommends both and has specified the best doses
of methacholine for each (27). However, in a study comparing accuracy of PC20 to PD20
using tidal breathing with nebulizers, PD20 was more consistent and recommended for
use in methacholine challenges (80). Tidal breathing incorporates measuring the tidal
expiratory flow and/or thoracoabdominal motion (79). The dosimeter method involves
using about half the delivered dose with deep inhalations (81). A caveat of using PD is
that the dose delivered to the airways can only be roughly estimated (78). While both
tests are used frequently, the type of test and nebulizer used has been shown to impact the
number of AHR positives (82). Using the dosimeter method has also been found to have
25% more false negatives in mild AHR compared to the tidal breathing method (81).
However, when using the 2-minute tidal breathing method as done in Dell et al. (80), the
use of PD is still preferred to PC.
Studies of Lung Function and Bronchoprovocation in Horses
Pulmonary function testing has been performed predominantly in horses with SEA.
A few studies will be reviewed in this section and their contributions discussed. The
effect of the -adrenergic system on asthma, as first proposed by Szentivanyi (32) has
been evaluated in BDA horses (83). Horses were given -adrenergic antagonists and
14

agonists that were nonspecific, as well as those specific for

1-adrenoceptors

or

2-

adrenoceptors during clinical remission and clinical exacerbation. The antagonists
decreased Cdyn and increased RL during exacerbation of BDA affected horses, but there
was no effect during clinical remission. Normal horses were not affected by the
antagonists. Agonists were able to attenuate airway constriction while bronchodilation
was specifically attributed to

2-adrenergic

receptor signaling.

In the late 1980s, Armstrong et al. performed bronchoprovocation in ponies with
BDA using methacholine and citric acid aerosolization (26). Lung function was
measured during clinical remission (2 months on pasture), after barn dust exposure, then
1 and 2 weeks after returning to pasture. The group found that BDA affected horses had
the greatest difference in pulmonary function parameters (Cdyn and RL) when tested after
barn dust exposure. The dose of methacholine causing a 65% decrease in Cdyn was lower
for BDA affected ponies than control ponies. Also, the change in RL and percent change
in Cdyn caused by 0.1mg/ml methacholine was higher in affected ponies compared to
controls. BDA affected horses did not maintain these parameter differences to the same
degree when in the period of clinical remission. However, Cdyn was decreased and RL
was increased in BDA affected ponies versus controls during remission. Once horses
were on pasture 1 and 2 weeks post barn dust exposure, Cdyn and RL returned to similar
levels as in clinical remission, indicating improvement in airway obstruction when the
inciting environmental triggers were removed.
Some things to note about this study are: 1) that the horses were sedated, and the
effect of sedation on lung parameters has been debated (84–86), 2) measurements were
obtained via an esophageal balloon passed through the nares, 3) horses were force
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ventillated before study, and 4) study end-point was when Cdyn reached 50% below
initial saline challenge. Using this endpoint 0.1mg/ml was the maximum dose of
methacholine administered.
In another study by Scott et al., a similar lack of AHR during clinical remission was
observed for BDA affected horses (87). Unlike the previously mentioned study, these
horses were not sedated during testing. Again, an esophageal balloon was passed through
the nares and attached to a pressure transducer. Histamine nebulization was done until
Cdyn decreased to 50% below baseline. The Scott et al. study also used a change in RL
from baseline to the 0.1mg/ml histamine dose as a measure of AHR (87). Before these
experiments in 1973, measurement of changes in lung function of BDA horses was
performed via a catheter inserted through a skin incision in the 16th intercostal space (70).
The catheter was inserted through the parietal pleura into the pleural cavity. A
manometer was attached to record intrapleural pressure measurements. Again, a decrease
in Cdyn was observed in horses with BDA compared to normal horses along with greater
work of breathing.
By testing affected horses with absences of clinical signs, two studies of pulmonary
function testing showed the horses with BDA were still hyper-reactive (69, 88). In one of
these studies measurements were made by using an esophageal catheter placed into the
nares to the 11th intercostal space (69). Using a face mask and pneumotachograph, a
single dose of histamine (62.5mg) was nebulized for the experiment. In this study, one
BDA affected horse was tested that lacked evidence of respiratory disterss and had
normal pulmonary function at rest. This horse showed significant hyper-reactivity to
histamine characterized by decreases in Cdyn , increases in ( Pplmax, and increases in RL.
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In the second study (88), BDA horses in remission were compared with healthy horses
using both impulse oscillometry and the traditional esophageal balloon method. Impulse
oscillometry (IOS) is a non-invasive system that generates a short, pulse signal at a high
frequency to determine respiratory impedance in a manner akin to forced oscillometry
which has been previously discussed (88). While this study first found that IOS
measurements were more sensitive than the esophageal balloon method, it also showed
that BDA horses could still be hyper-reactive while in clinical remission. A study by
Fairburn et al. (89) found that BDA horses still have AHR up to 3 days post allergen
challenge while in clinical remission. To this author’s knowledge, no study has yet to
evaluate the persistence of AHR in the EPA form of SEA, which is an objective of this
dissertation research.

Other Features of Asthma
There are three key defining features of asthma: reversible airway obstruction,
chronic airway inflammation, and persistent AHR. (2, 90, 91). Since AHR in SEA is the
focus of this dissertation, it has been previously discussed at length. Other important
features of asthma are discussed briefly here. Airway obstruction during asthma occurs
from airway narrowing due to bronchoconstriction (92). Other changes including mucus
accumulation and airway remodeling contribute to obstruction (92–94). The key in
asthma is that this obstruction is reversible, meaning that bronchodilation reverses the
asthmatic episode. Classically, reversibility is confirmed with the administration of an
inhaled ß2-agonist or a parasympatholytic agent.
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Prevalence of Human Asthma
According to the CDCs Morbidity and Mortality Weekly reports, the prevalence of
asthma has been increasing since 1960 (95–97). As of 2011, there were an estimated
39.5 million people affected with asthma in the United States (98). 1 in 12 adults are
affected with asthma, with estimates of increasing asthma prevalence in adults between
7.3% and 15% over the years 2001-2009 (17, 99). Asthma prevalence increased
significantly from 2001-2009 in 22 states, one of which was Mississippi (17). Other
southeastern states with a similar increase in asthma prevalence include Alabama,
Tennessee, South Carolina, and North Carolina (17), which is of particular interest to this
work as they constitute a region of the country in which EPA cases are concentrated.
Asthma costs for the United States in 2007 were estimated to be $56 billion due to
medical expenses, loss of productivity, and premature death (100). Productivity losses
such as those from morbidity that includes lost work and school days made up 8%-12%
of the total costs from 2002-2007 (100).
Certain populations are more likely to suffer from asthma. African-Americans are
more likely to be affected with asthma than Caucasians (95). In 2009 asthma was more
prevalent among females, non-Hispanic African-Americans, Puerto Ricans, those with
lower incomes, people living in the Northeast and Midwest, and children (101). Asthma
has also been shown to be higher among inner city children than other US populations,
with a large proportion of children reporting asthma-like symptoms with no actual
diagnosis (102). Similar to asthma seen in urban environments, which to some extent are
caused by house dust (103, 104), BDA is caused by exposure to dust particles in stables
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(14). These geographic and allergen similarities show important reasons to use SEA as a
translational model for human asthma.
Diagnosis of Human Asthma
A more in-depth review of diagnostic equipment and protocols was discussed
previously. A few points of relevance to the diagnosis of human asthma will be discussed
here. Pulmonologists commonly employ spirometry (2) or impulse oscillometry (IOS)
(105) in the diagnosis of human asthma. Spirometry assesses lung function by measuring
how much air is inhaled, exhaled, and the timing of exhalation (106). IOS is a forced
oscillation technique (FOT) requiring the patient to passively breathe while small
pressure oscillations are delivered through a mouthpiece (107). The National Asthma
Education and Prevention Program suggests diagnosis by a thorough patient history to
confirm recurrent episodes of reversible airway obstruction, a physical exam focusing on
abnormal sounds of the lungs, and/or spirometry (2). As previously indicated, the
magnitude of AHR is also quantified using methacholine bronchoprovocation in human
asthmatics as a means to characterize asthma severity (27). The American Thoracic
Society has indicated that severe human asthma is characterized by a 20% decrease in
forced expiratory volume in one minute by methacholine doses < 1 mg/ml. Methacholine
bronchoprovocation thresholds, clinical signs, and symptoms, useful for the diagnosis of
asthma are found in Tables 1 and 2.
Asthma is a separate disease from chronic obstructive pulmonary disease (COPD),
though roughly 20% of the population are diagnosed with both diseases (108). COPD, as
the name suggests, is characterized by chronic airway obstruction that is not reversible
(109). Reversibility is a key characteristic differentiating the two and must be addressed
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diagnostically in order to direct proper treatment of the patient for COPD versus asthma
(110, 111).
Once a diagnosis of asthma has been made, monitoring is generally considered to be
the responsibility of the patient. This may involve self-reporting such as keeping a diary
of attacks and symptoms, worsening of severity, response to therapy, or perhaps even
analysis of lung function via pulmonary mechanical testing (78). Recently, a number of
home monitoring devices have been made available to facilitate self-monitoring and
include SmartPhone applications such as the Asthma Health App
(http://apps.icahn.mssm.edu/asthma/). The CDC’s National Asthma Program
recommends each person receiving an asthma diagnosis be given a written action plan,
that includes daily instructions to reduce the chances of adverse events (1). Long term
asthma therapy aims to prevent triggers that cause difficulty breathing, moving to less
frequent use of short acting beta agonists (SABA) for quick relief, and allowing patients
to have a normal activity level with near normal pulmonary function (2). The difficulty
with meeting each of these expectations lies in the still evolving molecular pathogenesis
of asthma.
Airway Remodeling
Lung biopsy can aid in the diagnosis and characterization of severe asthma. While
both large and small airways are involved in asthma (112–114), much of the current
understanding of asthma has been derived from investigations of endoscopic biopsies
derived from large non-cartilaginous airways. A combination of changes including
thickening of the airway walls, smooth muscle cell hyperplasia and hypertrophy, fibrosis,
mucous metaplasia, and epithelial hypertrophy all are included in the over-arching term
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“airway remodeling” (49). Airway remodeling is the collective process of structural
alterations in cells and tissues in asthmatic airways (115). Epithelial injury can include a
loss of epithelial integrity, damage to the barrier function of epithelium via disruption of
tight junctions, and cell death all leading to worsening asthma severity (116–118).
However, damaged epithelial integrity has also been found to be no different from that of
non-asthmatics in bronchial biopsy, suggesting it may not be a unique feature of disease
(119).
One investigation of large airway biopsies from patients with severe human
asthma demonstrated thickening of the basement membrane and fewer inflammatory cells
in patients taking IC than those taking only

2-agonists

(113). Cartilaginous large airways

from cases of fatal asthma have also been identified to have greater total wall, inner wall,
outer wall, and smooth muscle area in fatal asthmatics relative to non-fatal asthmatic and
control cases (114). Similarly, the inner wall area of small non-cartilaginous airways has
been demonstrated to be greater in fatal versus non-fatal cases and controls (114). A
histologic scoring system was similarly developed recently and applied for the evaluation
of endobronchial biopsies from horses with BDA (120).
Mucus accumulation plays a role in obstruction to gas movement through the
airways. Changes include mucus production, mucin cross-linking, the degree of mucus
gel hydration, and mucus clearance (49). These changes in mucus are not limited to
severe asthmatics. Abnormalities in mucus production, storage, and clearance have been
seen in mild and moderate asthmatics as well (119). In addition to mucus accumulation,
ASM constriction plays a critical role in obstruction. ASM mediates
bronchoconstriction, hyper-responsiveness, and impacts lung function (121).
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Though large cartilaginous airways do contribute to asthma, modeling along with
inert gas washout and high-resolution CT have determined that the majority of airflow
obstruction during asthma occurs in small non-cartilaginous airways (122, 123). Despite
this, the relative inaccessibility of these airways has limited their histologic
characterization. By employing lung samples collected at necropsy, the histologic
features of airway remodeling noted in human asthma were evaluated in peripheral noncartilaginous airways from lung sections of EPA-affected and clinically normal horses
(6). Diseased airways had increases in ASM, goblet cell hyperplasia/metaplasia,
peribronchiolar fibrosis, airway obstruction by mucus/inflammation, elastosis, and airway
adventitial inflammation, all of which, are also found in human asthma (125–128).
Video-assisted thorascopic surgery (VATS) has become the gold standard to
evaluate the small non-cartilaginous airways of the distal lung in human patients (124).
VATS is not necessarily commonly performed in people with severe asthma, but has
been performed with a low incidence of post-surgical complications (124). In addition to
providing information about the remodeling status of the distal lung, VATS samples have
the potential to provide a wealth of research information as they are suitable not only for
histologic examination, but also for immunohistochemistry and diverse “-omics”
technologies including proteomics, transcriptomics, and metabolomics. In part reflecting
the increased risk and difficulty in attaining VATS samples, they present a particular
value in a biorepository form that could be beneficial in further aiding asthmatic research.
VATS was also employed in this dissertation research for biopsy of the peripheral lung in
order to evaluate the transcriptome of EPA horses and non-diseased controls during
seasons of asthma exacerbations and remission.
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Asthma Classification: Extrinsic versus Intrinsic
In 1949 Williams and Williams described the “asthma diathesis” that included a
familial history of disease, a history of allergic manifestations in the individual, and
abnormalities of the upper respiratory tract and bronchial tree as necessary for the
development of asthma (129). This asthma classification centers upon asthma arising
from a heritable predisposition to allergic disease which Rackeman described in 1947 as
reactivity to extrinsic allergens, giving rise to a classification system in which allergic
asthma is also termed ‘extrinsic asthma’ (130). Rackemann reasoned that the onset of
extrinsic allergic asthma presented initially in individuals under 30 years of age (130).
Among the allergic conditions that constitute asthma, the best characterized and
most common is atopic asthma, which reflects an inherited propensity of atopic
individuals to produce IgE in response to certain environmental antigens (131, 132).
Reflecting their increased IgE responses, atopic asthmatics also respond positively to skin
tests of common allergens. Allergens identified with atopic asthma include, but are not
limited to house dust mite, cockroach, molds, fungi, and animal dander (133, 134).
Because the prevalence of asthma has increased so significantly over the last few
decades, and genetic factors require much more protracted time frames to increase
asthma prevalence, environmental factors are postulated to be the most likely cause for
the reported increases in asthma prevalence (135). However, environmental factors
leading to asthma development are most likely to have a greater effect on individuals who
are genetically susceptible to the disease (135). In a review of population-based studies
evaluating family history of asthma and atopy, Burke at al. found that a family history of
atopic disease is a risk factor for asthma if that atopic disease is asthma (136).
23

Using a phenotypic algorithm, the loci 6p21.31, 9p21.2, and 10q21.3 have been found
in association with asthma in European Americans while the PTGES gene has been found
linked with asthma in African Americans (137). Meanwhile many genes have been
shown to occur with higher frequency in asthma populations. Interleukin 4-receptor
(IL4R) has been associated with severe asthma via genome-wide association studies
(GWAS) (138). Specifically, the allele IL4R-589T promotor polymorphism has been
associated with sudden-fatal onset asthma, and the allele IL4RA-576R amino acid
substitution is associated with severe airway obstruction (139).
An example of extrinsic asthma is occupational, or work-related asthma (WRA). It
is defined as a reversible respiratory disorder caused by exposure to substances including
mold, dust, chemicals, fragrances, etc. (140). WRA is estimated to cause roughly 15% of
adult asthma (141), and is typically caused by a sensitizer, most commonly a high
molecular weight agent, causing an increased IgE response (142). Agents known to be of
particular risk include animal allergens, plants and plant products, cereals and grains,
fungi, and insects (142). Cleaning agents and moldy environments are particularly
important factors in development of WRA (141). The type of exposure (i.e. chemical vs.
aerosol) can largely determine the severity of asthmatic response. In one example from
the 1970s, employees at an electronics factory exposed to soldering reported asthma-like
exacerbations (140, 143). In another example, fragrances have been demonstrated to
increase WRA (144).
In contrast to extrinsic asthma, Rackemann observed that patients whose asthma
began over 40 years of age were less likely to have allergic components to their asthma
and failed to respond to antigen desensitization (130). Postulating that factors inside the
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body were relevant in such asthmatics the term ‘intrinsic asthma’ was coined to address
non-allergic asthma phenotypes. Today intrinsic asthma is considered to be characterized
by lack of allergic propensity (145), lack of clearly Th2-mediated disease (146, 147), and
an absence of positive skin testing reactions to common allergens (130, 145). Intrinsic
asthmatics generally have more severe clinical disease (130). However, the extrinsic and
intrinsic terminology has several challenges which have resulted in the replacement of
these terminologies with allergic and non-allergic asthma (148) or atopic and non-atopic
asthma (147).
Classification of Asthma: Eosinophilic versus Non-eosinophilic
Of particular relevance to this work is the designation of asthma phenotypes as
eosinophilic asthma and non-eosinophilic asthma (149, 150). As their names suggest,
these terms respectively refer to airway inflammation in which eosinophils or another
inflammatory cell type (most commonly neutrophils) predominate. (151). Eosinophils
have been found at higher concentrations in mild to moderate asthmatics, while
neutrophils were higher among severe asthmatics (152–154). People who have died from
sudden asthma attacks have a higher neutrophil over eosinophil inflammatory cell type
(155). Neutrophils have also been found to be the predominant cell type in asthma
refractory to treatment with inhaled corticosteroids (IC) (156). Eosinophilic
inflammation is more consistently associated in children with acute asthma (157), while
neutrophils are more consistently associated with adult onset asthma (158). However,
both eosinophilic and neutrophilic airway inflammation can occur in all age groups (159).
Woodruff et al. (160) also divided asthmatics into Th2high and Th2low phenotypes.
Th2high asthmatics responded to IC and had higher IL-5 and IL-13 concentrations in
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bronchial biopsies than the Th2low subgroup. Others have identified Th2 controlled
inflammation due to upregulation of the inflammatory markers PGD2, HPGDS, and
CRTH2 (161). One investigation of severe asthma identified decreased Th2 and IL-17
responses and increased IFN-γ (162). Increased transcriptional expression of IL-17A
has also been identified in severe asthmatics (163). The chemokine CXCL8, which
codes for IL-8 and is induced by IL-17A, is also increased in severe asthmatics (163).
CXCL8 is the strongest neutrophilic chemoattractant in the lung (164).
Interestingly, the Th17 (inducing IL-17) immune response was found to be steroid
resistant, while the Th2 immune response was not (165), suggesting the Th2
inflammatory response may not play a role in, or has a sparing effect on steroid
resistance in severe asthma.
Neutrophilic influx leads to a cascade of airway changes by first stimulating
goblet cells to secrete mucus, which plugs airways and causes obstruction (166).
Neutrophil supernatant has been shown to increase responsiveness of bronchial
tissue sensitized with 0.1% albumin (167). A decline in lung function, demonstrated
by a decreased FEV1, has also been associated with increased neutrophils in sputum
(168). These changes may be responsible for the finding that sudden-fatal onset of
asthma was associated more commonly with neutrophilic versus eosinophilic
inflammatory cell influx (155).
Systems Biology Investigations of Asthma
Asthma is a complex disease that results from the interaction of genetic and
environmental factors. Extending from this realization is an increasing interest in research
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methods that can capture and model this complexity. “Omics” technologies include
research methodologies that are capable of identifying changes in the expression of
biomolecules such as genes, proteins, metabolites, and lipids across an entire genome,
and are particularly well suited to the goal of unraveling asthma’s complexity. These
technologies include transcriptomics, proteomics, metabolomics, and lipidomics among
others. Samples used for biomarker discovery with these technologies include whole lung
tissue, cells isolated from lung, BALF, induced or spontaneous sputum, exhaled air, and
blood (169). Application of systems biology approaches to study complex diseases is
facilitated by the availability of large datasets that are generated by ‘omics’ technologies.
Systems biology seeks “to understand biological systems, complex or otherwise, from the
interactions of their components, using computational and mathematical tools” (170).
Systems biology uses both clinical and experimental data in computational and
mathematical modeling to gain biological insight (171). The U-BIOPRED experiment is
a key example of an organized multicenter study that integrates data derived from
“omics” technologies using systems biology to discover the underlying mechanistic basis
of severe asthma and will be discussed below (172).
“Omics” technologies are rapidly evolving, and more platforms are being added.
Genome-wide association studies (GWAS) identify markers across complete sets of DNA
or genomes to find genetic variations associated with a disease (173). RNA-Sequencing
uses deep sequencing technologies for transcriptome profiling and to catalogue all
species of transcripts (mRNAs, non-coding RNAs, small RNAs, etc.) (174). Proteomics
seeks to identify differences in protein expression, and protein-protein interactions, while
also able to highlight post-translational modification, and identify temporal patterns of
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expression (175). A newer “omics” field called breathomics uses exhaled breath to
identify biomarkers (176, 177). This technique has been pivotal in the identification of
the fraction exhaled nitric oxide (FeNO) as a marker of eosinophilic airway inflammation
in human asthma (178–180). As a non-invasive procedure, breathomics could be
particularly useful in a clinical setting for children, and perhaps one day for equine
diagnostics.
The sequencing of the equine genome has allowed researchers the ability to use
molecular genetics platforms such as proteomics, transcriptomics, and microarrays to
study the molecular basis of disease processes (181). Ever improving structural and
functional annotation of the equine genome has aided researchers when using modeling
tools in systems biology (182). Previous work done in our lab has furthered functional
characterization the equine genome (183). Both structural and functional annotation were
improved by confirming protein expression through proteomics and adding to the Gene
Ontology (GO). The GO consortium aims to create a vocabulary that can be applied
across eukaryotes to describe biological information related to gene products (184).
Through the three ontologies of biological process, cellular component, and molecular
function, the goal is to keep the vocabulary malleable to changing biological knowledge
and amendable to updated annotations (184).
There have been seven studies that utilize “omics” platforms to search for differences
between SEA affected horses and clinically normal horses. Molecular approaches to the
study of SEA have helped to solidify the importance of the disease as a translational
model for human asthma. Studies done have found overexpression of cytokines and
genes including IL-4R (185), NOD2 (185), CXCL13 (186), IL-8 (187), and TLR4 (187).
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These genes have been found as overrepresented in human asthma studies as well (188–
194).
Using genome-wide scanning of two half-sibling strings of horses with a severely
BDA-affected stallion, two chromosome regions (ECA13 and ECA15) had genome wide
association with BDA (195). These regions included the genes Interleukin 4 Receptor
(IL-4R), Il-21R, chemokine (C-C motif) ligand 24 (CCL24), IL-27, prostaglandin E
receptor 4 (PTGER4), phosphodiesterase 4D (PDE4D), suppressor of cytokine signaling
5 (SOCS5), and IL-17R.
Racine et al. (185) then used the software Ingenuity Pathways Analysis (IPA ) to
compare proteins from BAL fluid of BDA affected and control horses to investigate the 8
genes identified by Swinburne at al. (195). IL-4R had the greatest number of interactions
in the pathway analysis, highlighting it as an important protein in the BDA development
signaling cascade. They also suggest the proteins SOCS5, NOD2, RPS6KA5, and
FOXP3 have importance as regulators.
Peripheral lung biopsies from BDA affected and antigen challenged horses as well as
clinically normal horses were taken for comparative differential expression analysis with
suppression subtractive hybridization (196). Genes found showing expression
differences that are associated with asthmatic airway inflammation included
PPP3CB/NFAT, RhoA, and LTB4/GPR44.
One investigation employed proteomic analysis to characterize the proteome of
BAL fluid from BDA horses. These investigators identified 100 differentially expressed
peaks (197). The highlighted proteins from this study were secretoglobin and transferrin
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for use as biomarkers of disease. Both were negatively correlated with BDA but
overexpressed in control horses.
In a more recent study, microRNA (miRNAs) from SEA horses and normal horses
were compared (198). Eleven significantly differentially expressed miRNAs were found,
and pathways analysis highlighted regulation of epithelial to mesenchymal transition and
PIP3 signaling pathway. These are key mediators of airway remodeling (199) and CD4+
T cell modulators (200) highlighting the relevance of the technique to examine future
novel biomarkers of disease.
Using peripheral blood mononuclear cells (PBMCs), an RNA-seq study of BDA
horses and controls challenged with hay dust found that the cytokine CXCL13 was
strongly upregulated (186). The study also found that genes involved with immune cell
trafficking, cell cycle regulation, and development were also differentially expressed in
affected versus control horses.
Finally, RNA-seq was used to identify transcriptomic differences taken from
endobronchial biopsies in response to inhaled allergen challenge (187). In this study,
neutrophil migration genes were centralized in interaction networks. Highlighted genes
from this study included MMP9, TLR4, MMP1, and IL-8. This study was able to find
significantly expressed genes and networks that are similar to those of human asthma,
highlighting utility of this technology for translational studies.
All of these studies were able to use a molecular approach to investigate the molecular
mechanisms responsible for SEA. The goal of these approaches is to highlight genes,
proteins, networks, or pathways that may later be considered as biomarkers of disease.
Human asthma molecular studies have the advantage of having access to larger
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population sizes available for study. Thousands of people may be studied at one time
(201). As an example, genome wide association studies (GWAS) done over the past 10
years have shown that genes including TSLP, TNFSF4, ADORA1, CHIT1, and USF1 are
associated with asthma disease (201). However, human studies present certain
challenges including difficulties in unifying the type and stage of asthma progression as
well as the nature and timing of therapy.
The concept of “personalized medicine” based on “omics” studies is a current topic of
great interest in human medicine (202, 203). It focuses on the ability of “omics”
technologies to identify unique aspects of an individual’s metabolic makeup both in
health and disease in order to direct medical diagnosis and management. Using “omics”
studies to identify the mechanistic basis of disease in individuals and to identify
therapeutic targets for individuals is now a reality that is increasingly being applied to the
human population (204, 205). In fact, in a recent study analyzing priorities for asthma
research, the use of “omics” technologies for diagnosis and prediction was one of the
most important tools discussed (206).
Genomic approaches are being pursued to characterize differences between the
various types of asthma in people (207). For instance, a population of Icelandic
individuals in whom asthma is disproportionately low were identified to have a loss of
function mutation in IL-33 which is a tissue-derived cytokine that induces and amplifies
eosinophilic inflammation and is considered a promising target for asthma and allergic
disease (208). More recently, a systems biology approach has shed light on the poor
steroid responsiveness that characterizes severe asthma, by determining that a protein not
previously understood to interact with corticosteroids, FAM129A, modulates steroid
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responsiveness in lung epithelial cells (209). Similar studies could be useful in further
differentiating BDA from EPA, though it may be that the two have similar genetic
mechanisms as various forms of asthma do (207). Still, differences between types of
asthma (i.e. adult onset vs. childhood) have been found at a transcriptomic level (210),
and should be considered for BDA and EPA analysis.
U-BIOPRED, Unbiased Biomarkers for the Prediction of Respiratory Disease
Outcomes, is a consortium of academic institutions, pharmaceutical companies, and
patient organizations with the goal of understanding mechanisms of asthma using
systems biology (211). Samples from this study have shown that patients with severe
asthma have worse quality of life (including anxiety and depression) than those with
mild/moderate asthma, higher incidences of nasal polyps and gastric reflux, lower lung
function, and sputum eosinophil counts higher than mild/moderate asthmatics (211). Use
of U-BIOPRED has also determined that in patients with severe asthma, pathways in
chemotaxis, migration, and myeloid cell trafficking are increased while B-lymphocyte
development, hematopoietic progenitor cells, and lymphoid organ hypoplasia is
decreased (212). Another similar systems approach proposed by Auffray et al. (213)
seeks to find functional and regulatory pathways that play central roles in severe asthma.
This is another collaborative effort utilizing global genome, transcriptome, proteome, and
metabolome data sets integrated with biological and clinical data to form predictive
models. Through computational and experimental models, well-classified phenotyping of
severe asthma will hopefully be achieved and used to aid the development novel
diagnostic and therapeutic biomarker targets (213).
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Additional studies using the systems approach have been done to elicit mechanisms of
severe asthma in particular. Transcriptome analysis has demonstrated that severe asthma
is associated with activated CD8(+) T cells but not CD4(+) T cells (214). Sputum and
blood transcriptomes of children and adults with asthma have identified gene expression
patterns that are able to differentiate near-fatal, severe, and mild/moderate asthma (215).
Clusters correlating with clinical, physiologic, and inflammatory characteristics of
disease could be grouped as: 1) history of intubation, lower pre-bronchodilator FEV1,
higher bronchodilator response, and higher exhaled nitric oxide levels. 2) hospitalized for
asthma, 3) normal lung function, lower exhaled nitric oxide levels, and lower inhaled
steroid requirements (215). Thymic stromal lymphopoietin (TSLP) is increased in
airway epithelium and lamina propria of asthmatics, but especially in patients with severe
asthma (216). It also correlates with severity of airflow obstruction (216). Sputum
transcriptome analysis has shown the chitinase-like protein (YKL-40) is more associated
in asthmatics with earlier onset and longer duration of disease, severe airflow obstruction,
and near-fatal asthma attacks (217). Using epithelial brushings from severe asthmatics
and controls has shown IL-13 is upregulated in severe asthmatics and is more pronounced
in the peripheral rather than central airways (218). Proteomic studies on severe asthma
have highlighted significance of proteins like galectin-3 (219), TGF- induced epithelial
mesenchymal transition (EMT) (220), and mitogen kinase kinase 3 (MKK3) (221), and
have found clusters differentiated by asthma severity (with the more severe having higher
sputum eosinophils) (222).
The most severe population of asthmatics are corticosteroid resistant and have their
own distinct genetic features (223). The role of IC treatment and the effect of severe
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asthma has also been studied with systems approaches. For example, a microarray found
that mRNA encoding cFLIP, a modulator of caspase-mediated extrinsic apoptosis
pathway, is decreased in corticosteroid resistant asthma (224). Microarrays done on a
murine model of asthma found that expression of FK506 binding protein 51 gene
(FKBP51) is increased after dexamethasone treatment (225). When FKBP51 expression
was then induced in peripheral blood mononuclear cells, FKBP51 expression was
significantly higher in severe asthmatics (225). In comparing sputum from severe
asthmatics with that of non-severe asthmatics treated with inhaled corticosteroids (IC),
brain-derived neutropenic factor (BDNF), B-lymphocyte chemoattractant
(BLC/CXCL13), and epidermal growth factor (EGF) were significantly increased in
severe asthmatics (226). Sputum with neutrophil counts greater than 70% were used to
look for differential expression between patients with severe, uncontrolled asthma and
controlled asthma (227). S1009A was highlighted as a potential biomarker of
neutrophilic inflammation in severe, uncontrolled asthma.

Vitamin D has been

proposed to enhance the effects of IC in severe asthma patients where IC alone are
ineffective (228). Bitter taste transduction receptors (TAS2Rs) are increased in
transcriptome analysis of children with severe, IC resistant asthma compared to normal
patients and have been confirmed using qPCR to be upregulated in leukocytes from adult
severe asthmatics (229). Himes et al. (230) compared ASM transcriptomes of severe,
fatal asthmatics and non-asthmatics when treated with vitamin D. 711 differentially
expressed genes were found in the ASM transcriptome of fatal asthmatics after vitamin D
treatment and included genes in the cytokine and chemokine categories. Follow-up
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experiments then showed that vitamin D could inhibit TNF induced IL-8 protein
secretion to similar levels in both the fatal asthma and control groups (230).
Together these studies have demonstrated that systems biology approaches can be
used to not only find biomarkers of severe asthma but can also be used to assess the
effectiveness of potential therapeutics targeting these biomarkers. As shown above,
asthma is a multifactorial disease, and it has many potential regulators. The increasing
advancement of these technologies will be important to further characterize specific
asthmatic phenotypes, most notably severe asthma that is refractory to IC.
Asthma is a dynamic disease for which “omics” platforms provide a unique advantage
in characterizing how asthma changes in its underlying biology as the disease progresses
in severity over time. Systems biology approaches allow for observations at selected
points in time to be compared with other time points on a global ‘genome scale’ level,
which provides a unique ability to decipher the biology behind these dynamic changes.
Overall, numerous mediators of disease have been highlighted using systems biology to
investigate “omics” samples from asthmatics. Certainly, the numbers of studies may
never be able to reach the same level in SEA. However, SEA possesses characteristics
that make it a superior translational model for investigating severe and neutrophilic forms
of human asthma. Beyond the demonstrated homologies between SEA and human asthma
that have been previously described, investigations of SEA can control for factors such as
environment, treatment, and treatment compliance which are not well addressed in
human studies, while also characterizing the natural progression of spontaneous severe
and neutrophilic asthma. By extension, despite any challenges, investigations of SEA that
employ systems biology and “omics” technologies have the unique and insightful
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potential to contribute to investigations of severe and neutrophilic human asthma in a
unique and novel manner.
Animal Asthma Models
Animal models for the study of disease have historically been, and are still, an
important part of biomedical research. This is because ethical considerations prevent
many studies on human subjects. The use of laboratory animals also has its own ethical
considerations and cadre of compliance mandates that must be addressed (231). The best
way to utilize various animal models of asthma is still being debated (232, 233), and
there is no one model that recapitulates all aspects of human asthma (234). Still,
understanding the pathophysiology and treatment of asthma, like many diseases, has
benefited from the use of animal models.
Animal asthma models can be divided into those that are induced and those that are
naturally occurring, also termed ‘spontaneous.’ Three animal species are reported to
naturally develop asthma-like disease: 1) Feline asthma, which is characterized by
eosinophilic airway inflammation (235, 236); 2) Equine asthma which has both a mild
and severe form that is characterized by mild increases in neutrophils and eosinophils and
moderate to severe increases in neutrophils, respectively (8, 14), and 3) asthma in dogs
which includes Basenji dogs as well as asthma in sled dogs and is analogous to exerciseinduced asthma (237, 238). While having the advantage of being naturally occurring, the
disadvantage of using spontaneous models is that they occur in outbred species whose
inherent biologic variation presents the potential to require large sample sizes to achieve
sufficient statistical power to identify true differences in experimental outcomes (239).
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Rodents make up the largest percentage of induced animal models (239). Coupled
with current statistics that 85% of drugs that originate from mouse models do not
effectively translate to their human disease counterpart (240, 241), the utility of
commonly employed induced animal asthma models has been questioned (241, 242). In
induced asthma models, the allergens responsible for sensitization can be delivered by
inhalation, subcutaneous injection, intraperitoneal injection, or through intranasal drops
(243). The most frequently used induction antigens and important findings from
investigations that employ them are summarized in Table 3.
The most commonly employed induced animal model for asthma is the mouse,
particularly the BALB/c strain (243). Protocols sensitizing mice with ovalbumin (OVA)
(244–246) , house dust mite (247, 248), cockroach antigens (249, 250), Aspergillus
fumigatus (251, 252) , and ragweed extracts (253) have all elicited an asthma-like
phenotype. These models have aided in the identification of important cytokine
pathways in the pathogenesis of asthma (254–258). Mice are popular because they have
many advantages. Mice are easy to breed and maintain and, consequently, can be studied
in large numbers (243). Their inbred nature is particularly advantageous because it limits
variability in testing, facilitating the recognition of differences in experimental protocols
with fewer animals than are needed for outbred individuals. There are also a wide variety
of transgenic mouse strains available to study (259, 260), which has accounted for their
massive popularity recently. For example, the most commonly used mouse strain
(BALB/c) is employed in asthma research due to their ability to develop good Th2
responses (261, 262).
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The most important disadvantage to murine models is the inability to maintain the
disease state over time. Mice eventually develop tolerance to the sensitizing antigen
(247, 263). Some groups have tried to develop chronic models with mice in order to
develop a more clinically representative phenotype (261). These models involve
exposing mice to an allergen for longer periods of time. A drawback with these models
was that long-term exposure could lead to a decreased inflammation and AHR (264).
After 55 days of being challenged 3 times a week with OVA, mice have been shown to
maintain a predominantly eosinophilic infiltrate and airway remodeling, characterized by
increased collage matrix deposition and ASM cell hyperplasia, up to 4 weeks after
challenge ceases (265). This study also identified AHR to be maintained on day 35 of
allergen challenge, but AHR was not identified one month after exposure stopped in
response to doses of methacholine from 3-100mg/ml methacholine (265).
The mouse phenotype is predominantly characterized by eosinophilic airway
inflammation (244), not the neutrophilic airway inflammation that has been associated
with severe human asthma. These eosinophils rarely degranulate in the mouse models of
asthma (266), whereas human eosinophils do (267). It should be noted that there is a
murine model that results in airway remodeling more typical of that seen in humans
(268). There is also a mouse asthma model elicited by sensitization to house dust mite
antigen that resulted in longer termed airway remodeling consisting of goblet cell
hyperplasia, collagen deposition, peribronchial accumulation of contractile tissue and
what the authors call severe, only partially resolved airway hypersensitivity to
methacholine up to 9 weeks after exposure (248). Despite these advances, many
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therapeutics developed from murine protocols have proven ineffective in clinical trials
(269, 270).
Another commonly used rodent for asthma studies is the rat. The Brown Norway is
the most commonly used strain. Like mice, rats have been sensitized with ovalbumin
(271, 272), HDM extracts (273), and additionally 2,4-dinitrophenylated (DNP)Ascaris/Bordetella pertussis vaccine antigen (274). Rats have a larger body size
providing an advantage for lung mechanics studies to non-specific bronchoconstricting
agents and allergen inhalation. Brown Norway, Wistar, Sprague Dawley, Lewis, and
Fischer 344 strains of rats have been shown to vary in response to sensitization, the most
common being the Brown Norway (274, 275). Strain responses can be found in Table 3.
Another rodent, the guinea pig, is one of the oldest animal models of allergic airway
responses (276, 277). Guinea pigs have been primarily sensitized to OVA and respond
with a predominance of airway eosinophilic inflammation and increased airway
responsiveness (278, 279). Guinea pigs are believed to be more eosinophilic in their
allergic responses than people, constitutively producing more eosinophils in their normal
‘non-sensitized’ lung then do humans. This is thought to be influenced by constitutive
production of eotaxin and RANTES in guinea pig lung (278). Guinea pigs have
parasympathetic cholinergic input to ASM that mediates airway contraction through
acetylcholine release at post junctional M3 receptors (258). Guinea pigs also have
nonadrenergic noncholinergic (parasympathetic noncholinergic) innervation, like
humans, that mediates airway dilation and is absent in rats and mice (279). However, the
sympathetic innervation of guinea pigs differs from humans in that guinea pigs have
extensive sympathetic innervation of their tracheal ASM with sparse to non-existent
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innervation of ASM in the intrapulmonary airways (278). Humans, on the other hand,
lack direct sympathetic innervation of ASM (280, 281). The majority of autonomic
relaxant tone is mediated by ß2-adrenergic sympathetic receptors on ASM in response to
noradrenaline release, with parasympathetic non-cholinergic nerves (nonadrenergic
noncholinergic nerves) also contributing to direct relaxant innervation of ASM in both
guinea pigs and humans (282).
Guinea pigs have extensive advantages when investigating allergic asthma, which
have been reviewed by Canning (281). Guinea pigs have well-characterized early and late
phase responses (283) and experiments with precision cut lung slices have shown more
agreement between pharmacological responses of guinea pig and human airways than
other rodents (284). However, guinea pigs have some receptors not present in human
airway smooth muscle such as neurokinin1 receptor (285) and contractile prostanoid EP1
receptors (286–288). In addition, few transgenic guinea pig models are available, and
guinea pigs are prone to develop tolerance after repeated challenges just like mice and
rats (289).
Cats are one of the few animals to spontaneously develop an asthma-like disease with
respiratory signs of coughing, sneezing, and dyspnea (290). A model that sensitized cats
to Ascaris suum has also been developed, with the animals developing AHR to
acetylcholine and an increase in eosinophils in BAL fluid (291). Characteristics of AHR
and remodeling in this model are detailed in Table 3. In the naturally occurring disease,
bronchial washes have had a mixed population of cells including eosinophils, neutrophils,
and macrophages, though positive bacteria cultures were also present in some of these
cases (290).
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Dogs have been challenged with Ascaris suum (292) and ragweed (293) to develop an
asthma-like disease. Beagles sensitized with ragweed had increased IgE. They also
develop prolonged AHR lasting up to five months after the final challenge (294).
Similarly, Ascaris suum sensitized dogs develop airway hyper-responsiveness (290).
Though ragweed sensitized dogs develop eosinophilic airway inflammation in BAL fluid,
they lack a relationship between persistence of AHR and the magnitude of airway
eosinophilic inflammation (295). Basenji greyhound crosses, that have a wide range of
inherited bronchial sensitivity, have been proposed as a spontaneous model for asthma
since they have shown bronchial responsiveness to hypotonic and isotonic aerosols (296).
When challenged with Ascaris suum, citric acid, and methacholine, Basenji greyhounds
responded to methacholine at concentrations 10-30 times lower than mongrel dogs,
confirming non-specific airway hyper-responsiveness (297). In the same study, citric
acid caused increases in RL at 5-10 fold lower concentrations than mongrels (297).
Interestingly, in the study, Basenji greyhounds responded to methacholine and citric acid
regardless of their Ascaris sensitization status (297), suggesting a baseline level of
bronchial hyper-reactivity in the breed. AHR also seems to be a characteristic of only the
Basenji greyhound cross, and not the Basenji or greyhound ancestral lines (298).
Larger animal models have also been used to study asthma. Since animals like sheep,
pigs, and calves have similar body weights as humans, they have been proposed as better
models to evaluate pulmonary function (299). Sheep have been sensitized to Ascaris
suum (300). Immediately after challenge RL increases, and Cdyn and PaO2 decrease (300).
Sheep that respond both early and late to an allergen challenge, termed “dual
responders”, have increased airway eosinophil percentages following challenge (301). In
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contrast, both early and late phase responders will also have an increase in airway
neutrophilic inflammation post challenge (302). Only dual responders have AHR (in this
study defined at 150% increase in RL) 24 hours after challenge (303). However,
therapeutics developed from sheep models have yet to prove effective in human clinical
trials (304, 305). Pigs have also rarely been used and were sensitized with Ascaris suum,
producing a late phase response with blood eosinophilia (306).
Finally, non-human primates have been used in asthma research, as well. Squirrel
monkeys (Saimiri sciureus) (307), rhesus macaques (Macaca mulatta) (308), and
cynomolgus macaques(Macaca fascicularis) (309) have been sensitized to Ascaris suum
and house dust mites (310, 311). After multiple challenges, cynomologus macaques
show AHR and eosinophilic inflammation to Ascaris suum (312). Inhalation challenge
with Ascaris resulted in increased RL in both types of single responders (acute or late
phase), while only dual responders maintained an increased RL for 6-8 hours after
challenge (312). Neutrophilic inflammation has been observed in primates after antigen
challenge with Ascaris suum, though to a lesser extent than eosinophilic inflammation
(309). In this study, the percent of neutrophils in dual responder primates was greater
than that of single responders. A direct relationship between the late phase response and
neutrophilic inflammation was, therefore, proposed. In fact, another study by this same
group found a late phase dependence on endothelial leukocyte adhesion molecule 1
(ELAM-1) for neutrophilic inflammation (313).
The inflammatory response of monkeys sensitized with house dust mite antigen
includes increased eosinophils in BALF and elevated CD25 expression on circulating
CD4(+) lymphocytes in peripheral blood (310). Sensitized monkeys exhibited clinical
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signs of obstruction such as coughing and rapid shallow breathing. An increase in R L that
could be reversed by nebulized albuterol was also present. This model also has
remodeling changes including mucus cell hyperplasia and epithelial cell hypertrophy in
rhesus monkeys sensitized to house dust mites (310).
It should be mentioned that the fruit fly, Drosophila melanogaster, has been proposed
as an animal asthma model due to potential homology of known asthma-susceptibility
genes between humans and the fly (314). The fruit fly has also been proposed,
particularly for GWAS comparison studies due to the similarity of the airway system’s
reaction to pathogens with mammals like the mouse (315). Due to their lack of lungs
(315), they are not an appropriate model for induction studies, however.
Animal models remain integral to our understanding of asthma pathogenesis. There is
no one perfect model that is able to address the multitude of disease characteristics that
exist across the spectrum of asthma. As evidenced in Table 3, it is difficult to find a
model that is able to answer all inquiries covered by various studies over time.
Accordingly, animal models that capture specific facets of diverse asthma phenotypes
constitute the best currently available research tools for investigating asthma.
Understanding the limitations imposed by each model system is essential for selecting the
appropriate model for a given hypothesis and for interpreting the resulting data within the
context of human asthma.
Summary
Asthma is a multi-factorial disease, which is not yet completely understood. With
increasing prevalence and costs of severe asthma, there is a growing need for animal
models to investigate pathophysiologic mechanisms of disease. Various studies of lung
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function, genetic mechanisms, and airway remodeling have been performed to this end.
Many of these studies have utilized animal models, but most rely on induction of disease
with antigens. Each model has advantages and disadvantages, but the largest drawback
of induced models is the lack of chronic persistence and ability to consistently model the
severe asthma phenotype. The horse, however, is unique since equine asthma develops
spontaneously and is characterized by neutrophilic inflammation, an inflammatory
characteristic that is reported to be associated with both severe and fatal human asthma.
This creates a special opportunity for investigations targeting the neutrophilic, severe
asthma phenotype. In consideration of the limited availability of spontaneous
translational asthma models and knowledge that

2-AR

signaling contributes to the

development of asthma in a murine model (ref), this dissertation first focuses on
confirming that EPA recapitulates both the magnitude and persistence of airway hyperthat characterize severe human asthma. Next, using a systems biology approach,
associations between

2-AR

signaling and genes that were identified as differentially

expressed in the lung of EPA horses were explored to identify a novel mechanism of.
ASM responsiveness. The overarching goal of this work was to validate Equine Pasture
Asthma (EPA) as a translational asthma model in order to identify novel therapeutic
targets for both horses affected with EPA and people suffering from severe asthma in
concordance with One Health Initiatives. This has been accomplished by: 1) using
methacholine bronchoprovocation to confirm AHR of EPA horses evident at
methacholine concentrations equal to that of severe human asthmatics, 2) RNAsequencing of lung samples of EPA and clinically normal horses to identify unique gene

44

targets for EPA disease, and 3) immunohistochemical and in vitro investigations of novel
gene targets found to be unique to EPA horses during disease exacerbation.

Table 1

Categories of airway hyper-responsiveness based on methacholine challenge
testing

PC40RL (mg/ml)
Analysis
>16
Normal
4.0-16
Borderline AHR
1.0-4.0
Mild AHR
<1.0
Moderate to severe AHR
Information found in Guidelines for Methacholine and Exercise Challenge Testing (27).

Table 2

Symptoms indicating consideration for equine asthma diagnosis

Symptom
Wheezing

Description
Whistling noise heard on
exhalation
Cough
Especially at night or when
waking
Chest tightness
Historical
Difficulty breathing
Historical
Information found in the National Asthma Education and Prevention Program Expert
Panel Report for diagnosing asthma (2).
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Table 3

Animal

Mice

Summary of some induced animal models of asthma with relevant findings

Antigens

OVA

House dust
mites

Animal
StrainsBreeds

Predominant Cell
Types
(Predominant Listed
First)

C57BL/6,
BALB/c,
A/J

Eosinophils

C57BL/6

Eosinophils,
persists for
up to 7
weeks and
decrease
with long
term (11
weeks)
exposure
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Magnitude
of AHR
Inhaled Mch
Range: 3100 mg/ml
- PC50 Mch
Elastance:
3.3 mg/ml
-Mch for
Significant
RL Change:
25, 50, and
100mg/ml
-Mch for
Significant
Penh
Change:
10,30,
100mg/ml
Dose
dependent
increase in
RL from 1.0100mg/ml
Mch;
Significant
difference in
AHR
between
sensitized
and control
mice occurs
after 5
weeks of
exposure

Remodeling

References

Collagen
matrix
deposition,
ASM
hyperplasia

(265, 316–
318)

Goblet cell
hyperplasia,
peribronchia
l
accumulatio
n of
contractile
tissue,
collagen
deposition

(247, 319)

Table 3 (continued)

Cockroach

C57BL/6

4-week-old
mice have
greater
inflammatio
n in airways
and
vasculature
(specific
cell type not
defined)

Aspergillus
fumigatus

BALB/c

Eosinophils

-

-

(251, 252)

-

Eosinophils,
neutrophils,
lymphocyte
s, and
macrophage
s

-

-

(253)

Ragweed
extract

47

4-week-old
mice have
higher RL
than control
mice at 40
and
50mg/ml
Mch

Peribronchi
al and
perivascular
inflammatio
n

(250)

Table 3 (continued)

Rat

OVA

Brown
Norway,
Sprague
Dawley

Eosinophils,
neutrophils,
mast cells

-

-

(271, 272)

House Dust
Mites

Brown
Norway

Eosinophils,
neutrophils

-

-

(273)

DNPAscaris/Bor
detella
pertussis
vaccine

Wistar,
Lewis,
Fischer 344

-

-

-

(274)
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Table 3 (continued)

Guinea Pigs

Cats

OVA

Ascaris
suum

DunkinHartley

Domestic
Short Hair

Eosinophils,
macrophages

AHR noted
12 hours
following
exposure
but abates
by 24 hours.
–AHR noted
with
0.5mg/ml
histamine

-

(278, 320,
321)

Eosinophils

Ach
challenge
with
resulted in a
1.0 log
decrease
eliciting a
200%
increase in
AHR 24
hours after
challenge;
1.5 log
decrease
eliciting a
200%
increase in
AHR
present after
4 to 6 weeks
of challenge
three times
a week
(reactivity
assessed 72
hrs after last
challenge)

Bronchocon
striction,
luminal
narrowing,
increased
smooth
muscle
thickness,
goblet cell
and submucosal
gland
hypertrophy
and
hyperplasia

(291)
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Table 3 (continued)

Dog

Sheep

Ascaris
suum

BasenjiGreyhound

Neutrophils

Ragweed

Beagle

Eosinophils

Ascaris
suum

-

Eosinophils,
neutrophils

50

RL increases
4-6 hours
after
challenge
AHR
persisted
after 5
months after
exposure to
ragweed
twice at 13day
intervals
and again
45 days
later.
-RL
increased
and Cdyn
decreased
for 6.5-8 hrs
postchallenge
with
carbachol
-Carbachol
(26.9 breath
units)
caused
400%
increase in
RL
- Dual
responders
(early and
late phase)
to carbachol
exhibit
AHR
greater than
baseline
values up to
24 hours
post
challenge

-

(292, 297)

-

(294)

-

(300, 302,
303, 322)

Table 3 (continued)

House Dust
Mites

Non-human
Primates

Pig

Merino
cross

Neutrophils,
eosinophils
(Initial
recruitment
of
neutrophils,
followed by
eosinophils.
Eosinophils
continue to
make up
inflammatory cell
type until 48
hours after
challenge)

Ascaris
suum

Cynomolgus,
Rhesus
macaque,
Squirrel
monkey

Eosinophils

House Dust
Mites

Rhesus
macaque

Eosinophils

Ascaris
suum

-

Late blood
eosinophils

-

Single
responders
had 298%
increase in
RL, and dual
responders
had 268%
increase
(determined
by forced
oscillations
on tidal
breathing)
Increased
AHR to
methacholine
-

-

(323)

-

(307–309)

Basement
membrane
thickening

(311, 324)

-

(306)

Notes: (-) indicates information not specified in study, OVA=ovalbumin, ASM=airway
smooth muscle, Mch=methacholine, RL=resistance, AHR-airway hyper-responsiveness,
Cdyn= dynamic compliance, Penh=enhanced pause
References-see Appendix
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CHAPTER II
HORSES WITH PASTURE-INDUCED ASTHMA DEMONSTRATE SEVERE
PERSISTENT AIRWAY HYPER-RESPONSIVENESS
Abstract

Rationale: Persistent airway hyper-responsiveness (AHR) is an asthma feature not
effectively recapitulated by induced asthma models. An animal model with severe, nonspecific and persistent AHR is advantageous for asthma investigation.
Objectives: To document magnitude and persistence of AHR in a naturally occurring
horse asthma model, equine pasture asthma (EPA), elicited by exposure to pasture
grasses during conditions of high heat and humidity and concentrated in the southeastern
United States.
Methods: AHR was evaluated using the two-minute tidal breathing protocol to identify
the methacholine concentration causing 40% increase in baseline lung resistance
(PC40RL) in 10 horses with EPA during the season of asthma exacerbation. To confirm
persistent AHR, PC40RL was re-evaluated in 5 of the 10 diseased horses during seasonal
asthma remission (approximately 3-34 months later). 1 additional horse was also tested
during asthma remission. 10 non-diseased horses also underwent bronchoprovocation.
Reversibility of airway obstruction was evaluated in 8 EPA horses during asthma
exacerbation by evaluating changes in dynamic compliance (Cdyn), maximum change in
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pleural pressure (ΔPplmax), and lung resistance (RL) in response to levalbuterol
administration.
Measurements and Main Results: PC40RL of diseased horses was <1 mg/ml methacholine
during the seasons of asthma exacerbation (0.0625-1.0mg/ml) and remission (0.251.0mg/ml). PC40RL of individual EPA horses did not differ significantly between
exacerbation and remission (p=0.2176), confirming persistent AHR. Control horses were
less reactive then diseased (p=0.0014), failing to react up to endpoint methacholine
dilutions (8-16 mg/ml). Airway obstruction was reversible (P < 0.05), characterized by
increased Cdyn, and decreased ΔPplmax and RL.
Conclusions: EPA is characterized by reversible airway obstruction with persistent nonspecific AHR at methacholine concentrations considered diagnostic of severe asthma (<1
mg/ml), confirming EPA’s high fidelity with defining criteria of human asthma.

Introduction

More than 39.5 million people suffer from asthma in the United States (98). CDC
estimates indicate that asthma affects 1 in 12 adults with a 15% increase in prevalence
from 2001-2009 (99). Asthma is estimated to cost the United States $56 billion/year from
medical expenses, loss of productivity, and premature death (100). While prevalence of
adult asthma varies between states, Mississippi saw a significant increase from 20012009 (99). In 2016, the Asthma and Allergy Foundation of America listed Jackson,
Mississippi as the most challenging capital in which to live with fall allergies (18).
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A severe asthma-like disease, termed equine pasture asthma (EPA), also affects adult
horses living on pastures during the summer months in the southeastern United States
(13). A parallel clinical phenotype previously referred to as ‘heaves’ or recurrent airway
obstruction (RAO) affects stabled horses in the winter in temperate regions (325–327)
and has been increasingly employed as a naturally occurring animal asthma model based
on similarities between the equine and human lung (328), ability to induce reversible
airway obstruction (329), and the ability to acquire thoracoscopic lung biopsies for
experimental analysis (330, 331). Whereas the stable ‘heaves’ phenotype is triggered by
indoor aero-allergens that accompany feeding hay (325), the phenotype affecting horses
on pasture in the southeastern US has been termed Equine Pasture Asthma (7) to address
the unique geographic, seasonal, and aeroallergen characteristics of the pasture associated
disease. Horses with EPA demonstrate progressive exacerbation of their clinical signs,
which include cough, wheezing, and respiratory distress during successive warm seasons
with periods of remission during cool seasons despite their continued housing on inciting
pastures (5).
Horses with EPA and stable heaves experience key facets of asthma including variable
airflow obstruction and chronic airway inflammation in which neutrophilic inflammation
predominates (22, 332, 333). While non-eosinophilic airway inflammation is identified
in at least 50% of adult asthmatic patients (149), neutrophilic airway inflammation
correlates to severe and treatment refractory asthma phenotypes (152, 155). Despite the
clinical relevance of non-eosinophilic inflammation in asthma, eosinophilic inflammation
predominates in animal asthma models (334). Both EPA and stable heaves provide the
only naturally occurring animal asthma model with neutrophilic airway inflammation.
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Non-specific airway hyper-responsiveness (AHR), a key facet of asthma diagnosis, has
been documented in horses with stable heaves (326) following challenge with moldy hay
but with no persistence of non-specific AHR 1 to 2 weeks following moldy hay
challenge. However, presence, severity and persistence of non-specific AHR has not been
documented in EPA.
Considering the strengths of EPA as a severe and naturally occurring asthma disease
with neutrophilic inflammation which correlates to disease severity in human asthma, the
objective of this investigation was to characterize key facets of asthma diagnosis, namely
the presence, severity and persistence of non-specific AHR and the reversibility of airway
obstruction in order to refine the phenotype of horses with EPA. This information will
improve the utility of this spontaneous animal model for investigating non-eosinophilic,
and adult asthma phenotypes, as well as environmental factors that impact asthma
prevalence in the southeastern United States.
We hypothesize that non-specific AHR in horses with EPA persists for protracted
periods beyond seasonal exposure to inciting aeroallergens. To test this hypothesis, we
characterize the magnitude of methacholine responsiveness in EPA affected horses
during periods of clinical exacerbation and remission.
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Materials and Methods

Study SubjectsTwenty-two horses (12 EPA affected and 10 clinically normal controls) were enrolled
in the study. The mean age of diseased horses was 19.9 years (SD=6.5 yrs). Control
horses were 20.6 years old (SD=4.2 yrs). Diseased horses included 7males and 5 females.
Control horses included 6 males and 4 females. EPA horses had 2 or more years of
recurring episodes of warm season asthma-like disease that remitted during cool seasons,
and a predominance of neutrophils on cytologic examination of BAL (12-97%,
mean=58.6%). Only 2 horses had 1 % eosinophils identified. Control horses were
selected from a closed herd also maintained in close proximity to principals at
Mississippi State University and were identified based upon historical and clinical
absence of seasonal respiratory distress in their lifetime. The study was approved by the
IACUC committee at Mississippi State University (protocols 11-, 14-016, 16-035).
Study DesignReversible Airway Obstruction
Reversible airway obstruction was documented in 8 horses experiencing asthma
during the season of clinical EPA exacerbation which is reported to span the months of
June through November (10). Horses were tested when their clinical score of respiratory
effort (CSRE) exceeded 5/8. CSRE is calculated based upon nostril flare and expiratory
effort as previously described (335). The effect of nebulized levalbuterol (1.25 mg) on
maximal change in pleural pressure (ΔPplmax), lung resistance (RL), and dynamic
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compliance (Cdyn) were determined using conventional pulmonary mechanics (67).
Pleural pressure was measured indirectly using a 10 cm latex balloon secured to a
catheter that was placed at the 11-13th intercostal space. The catheter was connected to a
pressure transducer (Validyne Model DP45-28, Northridge, CA). For each horse, balloon
placement was initially determined by passing the balloon and catheter through a
nasogastric tube that was introduced via the nares into the rostral esophagus. The balloon
and catheter were advanced into the stomach, inflated with 15 cc of air, and withdrawn
slowly to identify site of maximal negative deflection during inspiration between the
diaphragm and heart.(22) Flow was measured using a Fleisch #6 pneumotachograph
fitted into a mask (Air-o-mask, Trudell, Inc., London, Ontario) that covered the horse’s
mouth and nose(23). ΔPplmax, RL, and Cdyn were measured prior to and at 7 and 15
minutes after levalbuterol administration. All signals were recorded via Buxco
Biosystems XA software (v. 2.5). Pressure and flow signals were interfaced via a
preamplifier (Buxco Max II, Wilmington, NC) to Buxco Biosystems XA software (v. 2.5,
Buxco, Wilmington, NC).

Methacholine Bronchoprovocation
Following levalbuterol administration, horses were housed for 48-72 hours in a
climate-controlled stall until signs of respiratory distress abated. Each horse underwent
methacholine bronchoprovocation using the 2-minute tidal breathing protocol (27),
employing doubling concentrations of methacholine from 0.0625 to 16 mg/ml (337).
Based upon guidelines for noncompliant human subjects (79), the methacholine
concentration causing a 40% increase in baseline resistance (PC40RL) was determined.
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Control horses were similarly challenged except for 5 control horses that were poorly
tolerant of the instrumentation and were challenged with a single methacholine
concentration (16 mg/ml) via 2-minute tidal breathing. Measurements of RL for each
methacholine dose were derived from 10-20 representative breaths. To determine the
persistence of non-specific airway hyper-responsiveness, methacholine
bronchoprovocation was repeated in 5 EPA-affected horses during the season of EPA
remission (December-April) (10) when clinical scores of respiratory effort were
consistently <4/8. An additional horse also underwent methacholine bronchoprovocation
during seasonal remission which had not been previously tested the season of disease
exacerbation. At the end of each test, bronchodilation was induced using 1.25mg of
levalbuterol by nebulization.
Statistical Methods
Nonparametric models were employed because the data did not meet assumptions of
normality and homoscedasticity. For measures of reversible airway obstruction, the effect
of sample time on RL, Cdyn, and ΔPplmax was assessed by a method similar to the nonparametric Friedman’s test. The data was first ranked within each horse. Analysis of
variance for each of the outcomes using PROC GLM in SAS for Windows v9.4 (SAS
Institute, Inc., Cary, NC) was then conducted on the ranked data with sample time and
horse as fixed effects. Where the effect of time was significant, pairwise comparisons
were made between the Time 0 (baseline), Time 7, and Time 14 values, using Tukey’s
adjustment for multiple comparisons. Differences in RL values for horses in exacerbation
compared to control horses and for horses in persistence compared to control horses were
assessed with separate Wilcoxon Rank Sum tests using PROC NPAR1WAY in SAS for
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Windows v9.4. Differences in PC40RL values while horses were in exacerbation
compared to persistence were assessed using a paired t-test. An alpha level of 0.05 was
used to determine statistical significance.
Results

Reversible Airway Obstruction
Significant decreases in RL between T=0 and T=7 (p=0.0003), and between T=0
and T=14 (p<0.0001) were identified. A slight decrease in RL between T=7 and T=14
was not statistically significant (p=0.1134) (Figure 1A). ΔPplmax decreased
significantly between T=0 and T=7 (p=0.0003) and between T=0 and T=14
(P<0.0001). There was no difference in ΔPmax between T=7 and T=14 (P=0.6092)
(Figure 1B). Significant increases in Cdyn between T=0 and T=7 (P=0.0146) and
between T=0 to T=14 (P=0.0003) were also identified. Reflecting large variations in
Cdyn between T=7 and T=14, a slight increase Cdyn during this interval was not
significant (P=0.1389) (Figure 1C).
Methacholine Bronchoprovocation
When tested during the season of clinical EPA exacerbations, 10 EPA-affected horses
achieved their PC40RL at methacholine concentrations between 0.0625 and 1.0mg/ml
(Figure 2). During this season, control horses failed to develop significant increases in RL
at all tested methacholine concentrations (Figure 2). Accordingly, the maximal RL
achieved by EPA-affected horses in response to the PC40RL was significantly greater than
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the RL achieved by control horses in response to maximal methacholine concentrations
(p= 0.0014).
6 EPA-affected horses received methacholine bronchoprovocation during seasonal
EPA remission, achieving their maximal RL concentrations between 0.25-1.0mg/ml
(Figure 3). 5 of these horses had been tested between 3 and 34 months prior, during the
season of EPA exacerbations. Non-specific AHR persisted in all five horses tested. There
was no significant difference in the PC40RL for each horse between seasonal exacerbation
and remission (p=0.2176) (Figure 4). Three of the 5 horses achieved their PC40RL at
methacholine concentrations less than 0.1mg/ml difference between both time periods,
while two horses reacted to concentrations less than 0.4mg/ml during remission relative
to the preceding exacerbation test. (Table 1). The maximal RL achieved by EPA-affected
horses in response to the PC40RL during seasonal remission was significantly greater than
the RL achieved by control horses in response to maximal methacholine concentrations
(p= 0.0074).
Discussion
This investigation identified reversible airway obstruction, and non-specific AHR that
persists despite the absence of inciting aeroallergens for periods up to three years in
horses with documented equine pasture asthma. Neutrophilic airway inflammation with
minimal eosinophilic inflammation has been previously documented in horses with EPA,
and is a diagnostic feature of the disease (7, 22, 338). While the triumvirate of reversible
airway obstruction, inflammation, and persistent non-specific AHR are considered key
diagnostic features of human asthma (2, 109, 149), induced animal models are challenged
by the inability to adequately recapitulate these diagnostic features (235, 262).
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EPA-affected horses exhibit asthma while grazing pastures during summer months in
the southeastern United States, and demonstrate improvement, consistent with reversible
obstruction, when removed from the inciting pasture environment into a climatecontrolled stall (15). In this investigation, reversible airway obstruction was confirmed in
8 horses with EPA during a naturally occurring asthma attack, as evidenced by significant
decreases in RL, ΔPplmax, and a significant increase in Cdyn in response to the β2adrenoceptor agonist bronchodilator levalbuterol.
To quantify the magnitude of non-specific AHR in EPA horses, we determined the
concentration of methacholine that elicits a 40% increase in baseline RL (PC40RL) in 10
EPA affected horses. This threshold increase in RL was selected based upon methods for
methacholine challenge in non-compliant humans (26), because of the inability of horses
to voluntarily mount a forced expiratory maneuver (339). EPA horses achieved their
PC40RL at methacholine concentrations <1.0mg/ml, which have been previously
considered to be diagnostic of moderate to severe human asthma (24). Ten non-diseased
horses failed to react to methacholine doses of 8-16 mg/ml, congruent with methacholine
reactivity described for non-asthmatic human subjects (24). These results are of interest
because they substantiate that the methacholine reactivity of both normal and EPA horses
is physiologically relevant to non-asthmatic and asthmatic humans, respectively. This is
in contrast to the commonly employed mouse asthma models, whose magnitude of AHR
at baseline and following antigen sensitization, as measured by methacholine
responsiveness, is not well aligned to that of non-diseased and asthmatic humans
(27, 79, 316, 317). In addition, during methacholine bronchoprovocation clinical signs
associated with asthma including increased abdominal effort, higher respiratory
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frequency and coughing were noted in EPA horses with increasing methacholine
concentrations (data not shown). Congruent with previous findings for human asthma
(26), baseline RL and the magnitude of AHR, as documented by the PC40RL during
methacholine challenge, differed between horses in this investigation.
Like human asthmatics, EPA horses were demonstrated in this investigation to have
non-specific AHR that is persistent. Persistence of non-specific AHR to methacholine
was confirmed in 5 EPA affected horses with the durations between re-evaluation being 3
to 34 months. Though the sample size of 5 horses tested for persistence could influence
the lack of statistically significant differences in PC40RL between the 2 time points, two
points are noteworthy. First, 3 of 5 horses achieved their PC40RL at near identical
methacholine concentrations at each of the two separate evaluations. Second, the PC40RLs
of the remaining two horses during the two separate evaluations were within a single
doubling dilution. In its guidelines for methacholine challenge, the American Thoracic
Society has previously reported that methacholine reactivity within 1.5 doubling doses
over short time periods is not considered significantly different (27). Accordingly, there
is strong evidence for persistent and non-specific AHR in EPA.
Mouse models sensitized to ovalbumin and house dust mite, as well as rat and guinea
pig asthma models, which are commonly employed (247, 271, 273, 316, 340), present
several shortcomings as asthma models that were not identified in EPA horses. First,
rodents do not spontaneously develop asthma (248, 252, 271, 340–343). Second, rodents
do not develop AHR that persists for protracted periods beyond the duration of antigen
sensitization (247, 334, 344). Further, as previously indicated, in most rodent asthma
models the magnitude of AHR, as measured by methacholine reactivity, is not within
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physiologic ranges that are typical of human asthma (247, 316). Finally, rodent models
develop tolerance to their sensitizing antigen, which is also not a characteristic of human
asthma (263, 334, 344). By contrast, EPA is a lifelong disease that worsens in successive
years in affected horses that remain in the southeastern US (7), indicating that specific
AHR persists in EPA horses for life. Similarly, in the BDA form of SEA commonly
termed heaves, which is a spontaneous asthma model, tolerance to the sensitizing antigen
most commonly employed (moldy hay) has not been reported. However, persistence of
non-specific AHR to methacholine after hay and straw challenge has been reported to
persist for as few as 3 days following antigen sensitization (89). Though rodent asthma
models are cost effective, with an unprecedented array of immunologic reagents and
ability to generate diverse strains necessary to adequately investigate the molecular
underpinnings of asthma, the inability of rodent models to recapitulate aspects of AHR
that are well aligned between EPA and human asthma highlights the strengths and
relevance of EPA as a translational asthma model.
While addressing important aspects of AHR, the neutrophilic airway inflammation
that characterizes EPA BALF also supports the relevance of EPA to a population of
asthmatics that are not well modeled by other animal models. Murine models are
characterized by eosinophilic inflammation rather than neutrophilic (27). This makes
them ineffective in modeling the population of asthmatics that are demonstrated to be
most likely to have fatal attacks (155). Further, while some investigations have identified
eosinophilic airway inflammation in more severe asthmatics (345), Wenzel et al. (149)
identified a subset of people suffering from severe asthma characterized by
predominately neutrophilic inflammation. Though the neutrophilic phenotype has been
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reported to be present in approximately 50% of patients with symptomatic asthma (346),
it remains poorly modeled in translational studies where eosinophilic airway
inflammation predominates (247, 265, 317, 343). Neutrophils also predominate in people
with corticosteroid resistant asthma, which is now considered a defining criteria for
severe asthma (347). Accordingly, EPA presents a translational asthma model that
encompasses aspects of AHR that have been previously associated with severe human
asthma, while also demonstrating neutrophilic BALF infiltrates that segregate with severe
asthma, indicating that EPA provides an appropriate animal model for the study of noneosinophilic, severe asthma.
While working with a large animal species has associated increased costs, EPA
affected horses used in this investigation had been previously diagnosed with
documented histories of seasonally recurring asthma signs and exhibited naturally
occurring asthma exacerbation of sufficient severity and consistency to document
reversible airway obstruction using conventional pulmonary mechanics. The seasonal
recurrence of EPA exacerbations provides high fidelity as a disease for the study of
severe asthma based upon its natural occurrence, chronicity, and pathologic and
physiological similarities to severe, non-eosinophilic asthma in humans. The prevalence
of EPA in a region of the United States seeing a significant increase in the number of
adults reporting to be severely asthmatic increases the relevance of further study of EPA.
Here we have demonstrated that an equine asthma model with spontaneous reversible
airway obstruction and neutrophilic BALF inflammation recapitulates persistent and nonspecific AHR that characterize severe human asthma, in a manner that other translational
models lack.
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Horse with EPA have reversible airway obstruction.

The average maximum change in pleural pressure (A), resistance (B), and dynamic
compliance (C) of 8 horses experiencing EPA exacerbations (baseline) and changes in
these parameters at 7 and 14 minutes following the nebulization of 1.25mg of
levalbuterol are graphed. Error bars represent standard error of the mean. * significantly
different from T=o (p<0.05)
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Figure 2

Horses with EPA are hyper-responsive to inhaled methacholine.

The average % change of lung resistance (RL) from baseline was determined for horses
with EPA and clinically normal horses in response to serially increasing concentrations of
inhaled methacholine. Concentrations of methacholine <1mg/ml induced a 40% increase
in baseline resistance (PC40RL), while control horses failed to demonstrate significant
increases in RL to methacholine concentrations up to 8-16 mg/ml (p<0.0014). Error bars
represent the standard error of the mean.
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Season

Figure 3
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Average % change in resistance for methacholine challenge in EPA horses
by season.

Average % change from baseline in resistance for EPA affected horses in exacerbation
and remission seasons. Graphs included bars for standard error the mean.
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PC40RL

PC40RL of EPA Horses During Seasons of Exacerbation
and Remission
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Figure 4

Remission

PC40RL of EPA horses during seasons of exacerbation and remission.

PC40RL of five EPA horses receiving methacholine bronchoprovocation in seasons of
exacerbation and remission. No significant difference was found between seasons for
any of the horses tested (p=0.2176).
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Table 4

Comparison of PC40RL between horses in exacerbation and remission
seasons
Horse

PC40RL in
Exacerbation (mg/ml)

PC40RL in Remission
(mg/ml)

1
2
3
4
5

0.50
0.72
0.49
0.18
0.18

0.36
0.40
0.43
0.20
0.21

References-see Appendix
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Months Between
Exacerbation
and Remission
Testing
34
30
3
19
9

CHAPTER III

INCREASED HCN4 EXPRESSION ASSOCIATED WITH AIRWAY SMOOTH
MUSCLE DURING ASTHMA-LIKE DISEASE IN A SPONTANEOUS
ANIMAL ASTHMA MODEL

Main

Airway hyper-responsiveness (AHR) is a defining criterion of asthma that is impacted
by airway smooth muscle excitability (348). Decreasing AHR in asthmatics heralds
decreased asthma severity (27), making it a pharmacologic goal in the development of
asthma therapeutics (349). Hyperpolarization Activated Cyclic Nucleotide-Gated
Potassium (HCN) channels generate hyperpolarizing (‘funny’) current (Ih or If) that
regulates membrane excitability in cardiac muscle and nerves (350), in association with
smooth muscle in certain organs systems (351–354). HCN channels have recently been
demonstrated to modulate autonomic control of ASM in guinea pigs (355), but have not
been identified in ASM. Herein, we demonstrate a significant increase in HCN4 message
in lung tissue during exacerbation of a spontaneous asthma-like disease in horses.
Validation of this finding in a separate cohort of horses with asthma identified increased
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expression of the HCN4 protein to be localized to ASM, and to a lesser extent airway
epithelium during asthma exacerbations. Less HCN4 protein was identified in ASM
collected during asthma remission relative to exacerbation, but HCN4 protein was not
identified in lung tissue from control horses. The HCN4 channel blocker ivabradine
caused dose-dependent inhibition of carbachol-induced contraction in isolated bronchi
from horses with asthma, as well as from control horses. Collectively, these findings
indicate that HCN4 mediated current in ASM contributes to airway contractile responses.
HCN4 function has been deciphered in the SA node, where If current determines heart
rate by influencing the rate of diastolic depolarization (356). Accordingly, the presence
of HCN4 channels in ASM identified in this work indicates that If current has a role in
ASM excitability. Increased HCN4 expression in ASM during asthma-like disease then
advances a paradigm in which changes in the magnitude of If current contribute to ASM
excitability, presenting the potential to direct novel asthma therapeutics.
Associations between long-acting β2-adrenoceptor (β2-AR) agonist use and severe
asthma exacerbations (357) and asthma related deaths (358) highlight a critical need for
novel asthma therapeutics. Translational discovery is challenged by commonly employed
animal asthma models which are induced and do not adequately mirror the human
condition (299, 334). To improve the translational relevance of discovery, we investigate
the spontaneous equine asthma model (14, 299, 334), specifically the endotype that
affects horses grazing pasture during conditions of heat and humidity termed Summer
Pasture Associated Recurrent Airway Obstruction (SPARAO) (10), and more recently
termed Equine Pasture Asthma (EPA) (7). EPA affected horses demonstrate clinical
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features of asthma including reversible airway obstruction, airway hyper-responsiveness
(359), chronic inflammation and asthmatic airway remodeling (6). EPA horses exhibit
seasonal exacerbation remission cycles and are clustered in the southeastern United
States (10). Neutrophils rather than eosinophils predominate in the BAL fluid of affected
horses (22), mimicking a population of human asthmatics that are not well modeled by
eosinophilic airway inflammation that predominates in rodent asthma models (299, 334).
Genes segregating with asthma-like disease were identified using differential
expression analysis (RNA Sequencing) by comparing transcriptomes from serially
sampled lung biopsies. Biopsies were collected during disease remission and
exacerbation in both EPA-affected and non-diseased control horses. 1376 genes had
seasonal differential expression conserved in diseased horses but were not differentially
expressed by season in control horses (Online supplement table 1). Among these 1376
DEGs were genes with demonstrated relevance to asthma (Online supplement table 2),
including potassium calcium-activated channel subfamily M regulatory beta subunit 1
(KCNMB1) (360), tumor necrosis factor (TNF) (361), and synaptotagmin (362),
substantiating the translational relevance of our approach to the human condition. Based
on evidence that β2-AR signaling is necessary for the asthma phenotype in a murine
model (363), and that long-acting β2-AR agonist use increases severe asthma
exacerbations (357) and asthma related deaths (358), we sought genes with functional
relevance to β2-AR signaling that were not previously investigated in asthma to identify
novel facets of asthma pathophysiology. Among these, (HCN4), belonging to the gene
family that regulates membrane excitability (350), was targeted based upon evidence of

74

strong selective differential regulation directly linked to asthma-like disease (e.g. raw
read counts approaching zero during disease remission in both affected horses and in
control horses with significant expression during seasonal exacerbation only in diseased
horses).
Though there is ample evidence of HCN4 transcription in human lung expression
databases (363, 364), evidence of HCN4 translation in the lung and its cellular location
are absent. To confirm increased HCN4 expression at the protein level in our asthma
model, and to localize its cellular expression, HCN4 protein was stained in archival lung
tissues collected from an unrelated cohort of EPA-affected and age matched control
horses. Immunohistochemical staining confirmed strong HCN4 protein expression in
ASM, and to a lesser extent in airway epithelium during disease exacerbation (Fig 1A-C),
contrasting non-diseased age matched control lung harvested during seasonal disease
exacerbation in which HCN4 staining was not identified (Fig 1D-F). In lung harvested
from diseased horses during seasonal disease remission, HCN4 staining remained evident
but reduced in ASM and was rare in bronchial epithelium (Fig 1 G-I), in comparison to
HCN4 staining during clinical disease (Fig 1 A-C). HCN4 staining in ASM of diseased
horses during remission (Fig 1 G-I) was clearly greater than the nadir of expression
demonstrated by control horses (Fig 1 D-F).
To identify the effect of HCN4 inhibition on bronchial ring contractility, we tested the
effect of various concentrations of ivabradine, a known specific HCN4 blocker, on
tensions generated by isolated equine bronchi in response to the constriction agent
carbochol. Evaluations were performed on the day of lung harvest and repeated 24 hours
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later. Disease status had no significant effect on the degree of contraction generated.
However, this finding may reflect the fact that only 3 of 12 EPA horses employed in this
investigation were euthanized during disease exacerbation when HCN4 expression in
ASM is significantly increased. Significant interactions between concentrations of
ivabradine and carbachol were identified, highlighting the need for further investigation
into the mechanistic basis of ivabradine inhibition of ASM contractile responses.
Materials and Methods
Animal Tissues
A total of 27 horses, 12 with a diagnosis of EPA and 15 control horses without
EPA were used in this investigation. Diagnosis of EPA was based on seasonally recurring
and reversible obstructive respiratory disease when exposed to pasture during summers in
Louisiana or Mississippi. Signs of disease included overt respiratory distress, pronounced
expiratory wheezes throughout the lung fields, fluid in the trachea upon auscultation,
intermittent cough, and airway neutrophilic inflammation (>10% non-degenerate
neutrophils in BAL fluid and/or histologic evidence of neutrophilic airway inflammation
in lung sections). Control horses lacked evidence of respiratory disease and had <3%
neutrophils in BAL fluid and/or an absence of neutrophilic airway inflammation in lung
sections. In 26 of the 27 horses, the diagnosis as EPA or control was confirmed at
necropsy from gross and histologic pathology as we have described previously (6,22)
During disease remission, EPA-affected horses had normal bronchovesicular sounds
during auscultation of the lungs with the aid of a rebreathing bag. Limited neutrophilic
airway inflammation was confirmed in EPA-affect horses during remission by <10%
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non-degenerate neutrophils in BAL fluid and/or direct histologic evaluation of the
airways as described (6,22). Airway hyper-responsiveness was confirmed and quantified
using methacholine bronchoprovocation in 6 of the 12 EPA horses, as described in the
previous chapter, identifying a 40% increase in lung resistance in response to
methacholine doses <1 mg/ml. Tissues were harvested from animal procedures approved
by the Animal Care and Use Committee of Mississippi State University except for
archival tissue used for immunohistochemical staining which was harvested from animal
procedures approved by the Animal Care and Use Committee of Louisiana State
University.
Serial lung biopsies for transcriptome analysis were acquired from two EPA
affected horses during asthma exacerbation and remission via standing thorascopic
surgery. Diseased horses were paired to non-diseased control horses sharing the same
environment that were similarly biopsied. EPA affected horses were Tennessee Walking
Horses: an 18-year-old castrated male and a 17-year-old female. Control horses were
castrated male American Quarter Horses aged 18 and 13. Lung biopsies were stored at 80°C in RNALater preservative (Ambion, Austin, TX).
Immunohistochemical staining was performed on archived formalin-fixed,
paraffin embedded lung. Tissues had been collected immediately following humane
euthanasia from 3 EPA-affected horses (7, 16, and 19 years old) and 3 age matched nondiseased control horses that were euthanized during seasonal disease exacerbation. This
diseased cohort included 1 Appaloosa, 1 Quarter Horse, and 1 Welsh Pony; 2 castrated
males and 1 female; controls included 2 Quarter Horses and one American Saddlebred, 1
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castrated male and 2 females. 2 female EPA-affected horses, both Quarter Horses, 12 and
17 years of age, were euthanized during disease remission. The magnitude of neutrophilic
inflammation and gross postmortem findings in this EPA cohort has been previously
correlated to disease severity and peribronchial inflammation (22).
Bronchial rings were harvested from the right lung of seven EPA-affected and ten
clinically normal horses for use in tissue bath analysis. EPA affected horses consisted of
6 castrated males and 1 female, mean age=17.0 years (sd=6.68), 4 Quarter Horses, 1
Paint, 1 Appaloosa, and 1 Mustang. Control horses consisted of 6 castrated males, 4
females, mean age= 18.1 years (sd=7.89), 9 Quarter Horses, and 1 Dutch Warmblood.
Horses were sedated with xylazine (0.33-0.66 mg/kg) followed by humane euthanasia
with sodium pentobarbital (100mg/kg). The lung was quickly removed from the thorax
and placed in chilled modified Krebs-Henslett solution (KHS), which was also poured
into the right mainstem bronchus. Bronchial rings (approximately 4-5mm in diameter and
3 mm thick) were dissected from the right caudodorsal lung lobe and incubated in KHS
in 24 well plates at 4o C until assayed.
RNA Sequencing and Differential Expression Analysis
Total RNA was isolated from equine lung biopsies using Qiagen RNeasy Maxi
protocol (Qiagen Inc., Valencia, CA, USA) per the manufacturer’s instructions. Paired
end sequencing of isolated RNA (RIN= 7.1-9.3) was performed using Illumina TrueSeq
v2. with Hi-Seq 2000 v3. chemistry (Illumina, San Diego, CA). Differential expression
analysis was limited to the forward reads. Filtration and trimming were performed
using FAST QC (Brabham bioinformatics,
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http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). Reads were aligned to the
equine reference genome (GenBank Assembly ID: GCF_000002305.1) with Bowtie
21s (http://bowtie-bio.sourceforge.net) and differential expression determined
using ERANGE2s.
Gene products with significant differential expression (DEGs) between seasonal
exacerbation and remission at a 5% false discovery rate (FDR) were identified for each
horse, sorted, and matched to identify a set of DEGs common to both affected horses and
a second set of DEGs common to both control horses. From these two sets, differentially
expressed gene products present in affected horses, but absent in control horses, were
identified.
Immunohistochemistry
Translation of HCN4 mRNA, its differential expression in association with disease,
and cellular localization were confirmed using immunohistochemistry. Lung sections
were incubated at 75°C to remove excess paraffin. Slides were placed in serial alcohol
dilutions for a total of three minutes to remove excess paraffin: 100% xylene, 100%
xylene, 1:1 xylene to 100% EtOH, 100% EtOH, 100% EtOH, 95% EtOH, 70% EtOH,
50% EtOH, and deionized water to rinse. Antigen retrieval was performed for 30 minutes
using a vegetable steamer. Dako’s target retrieval solution (Dako North America Inc.,
Carpinteria, CA, USA) was used for antigen unmasking. Slides were treated with 0.2%
Triton-X100 (Sigma-Aldrich, St. Louis, MO, USA) in TBS for 20 minutes to induce
membrane permeability and blocked with Dako’s serum free universal protein block
(Dako Inc). To minimize background, an avidin/biotin blocking step was performed
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according to manufacturer’s instructions (Vector Laboratories Inc., Burlingame, CA,
USA).
Slides were incubated with rat monoclonal anti-HCN4 (Abcam ab32675, Cambridge,
MA, USA), 1:1500 for 16 hours and then treated with H2O2 for 10 minutes. A
biotinylated link and streptavidin conjugated to HRP were applied for 45 minutes (Dako
LSAB+ Detection System), followed by DAB chromogen for 10 minutes (Dako). Slides
were then counterstained with hematoxylin for 2 minutes, dipped in 0.3% ammonia,
mounted and cover slipped. Differential staining for HCN4 in lung samples was
evaluated using light microscopy by a board certified veterinary pathologist.
Effect of Ivabradine on Carbachol Induced Bronchial Contraction
Each tissue bath assay consisted of four bronchial rings that were suspended to force
transducers in the EMKA Bath 4 system (Emka Technologies, Falls Church, VA). During
harvest of the bronchial rings, efforts were made to isolate at least 4 rings from a single
bronchus to populate each assay. Prior to assay, bronchial rings were gently blotted with
filter paper, and trimmed to identical mass within 0.01 grams. Bronchi were suspended to
force transducers within isolated baths and equilibrated with 2g tension for 120 minutes
in KHS with carbogen (95% O2, 5% CO2) aeration. Two bronchi were pretreated with
ivabradine for 15 minutes, beginning at 1uM. Carbachol reactivity was characterized for
all four bronchi using serially increasing half log concentrations of carbochol (0.1nM33uM) every 15 minutes. Force (g) was measured continuously and recorded in 5
minutes intervals. The process was repeated with 4 new bronchial rings for each
additional ivabradine concentration: 3, 5, and 10uM. In addition, bronchial rings were
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incubated overnight at 4 C in KHS and the experiment was repeated the following day.
The contractile response of each bronchial ring was then calculated as a percentage of the
maximal contraction achieved.
Statistical Methods
Effects of disease status, ivabradine dose, and carbachol dose on the contractile
response were assessed in separate mixed multivariable linear regression models
developed for Day 1 and Day 2 measurements using PROC MIXED in SAS for Windows
9.4 (SAS Institute, Inc., Cary, NC). Disease status, ivabradine dose, carbachol dose, all
two-way interactions, and the three-way interaction were initially included as fixed
effects. The dose group within horse and horse identity were included as random effects
in the models. The interaction terms, starting with the three-way interaction term, were
sequentially removed from the models if not statistically significant. Disease status,
ivabradine dose, and carbachol dose remained in all models even when they were deemed
to not have a statistically significant effect. A LSMESTIMATE statement with
SIMULATE adjustment for multiple comparisons was used to make comparisons
between ivabradine dose at each carbachol dose for the ivabradine dose x carbachol dose
interaction in both models. In addition, for the Day 2 model, comparisons were made
between affected and control groups at each carbachol and at each ivabradine for the
Disease Status x carbachol dose and Disease Status x ivabradine interactions,
respectively. While Disease status was initially significant, significance did not hold
when broken down by ivabradine and carbachol dose.

The distribution of the

conditional residuals was evaluated for each model to assess if the assumptions of
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normality and homoscedasticity had been met. An alpha level of 0.05 was used to
determine statistical significance.
Discussion
Employing a self-controlled RNA sequencing protocol in which serial lung biopsies
were collected during asthma exacerbation and remission in horses with naturally
occurring severe asthma and paired controls, HCN4 message was identified to be
increased during asthma exacerbation. Using immunohistochemistry, increased HCN4
protein expression was confirmed in the lung of a second cohort of asthmatic horses that
were sacrificed during exacerbations of severe asthma. Histochemical staining localized
the increase in HCN4 protein expression during asthma exacerbations to ASM and
epithelium. Further, lung from age matched asthmatic horses that were sacrificed during
asthma remission also demonstrated HCN4 expression in ASM that was decreased
relative to HCN4 expression in ASM of asthmatic horses sacrificed during asthma
exacerbation. By contrast, HCN4 protein was not identified in the lung of age matched
control horses using immunohistochemistry. Collectively, these findings indicate that
HCN4 expression is constitutively increased in epithelium and ASM of horses with
asthma during remission with a significant increase occurring in ASM in association with
asthma exacerbations. To our knowledge, this is the first report of differential expression
of HCN4 and its localization to ASM and epithelium in association with asthma.
HCN channels, as reviewed by Postea (350) are six transmembrane domain, single
pore-loop cation channels capable of activation by membrane hyperpolarization or cyclic
nucleotide binding. Four HCN isoforms (HCN1-4) are characterized with differing tissue
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distributions, activation kinetics, and cAMP sensitivity. The resulting cation current is
termed funny current (If) because channel opening is activated by membrane
hyperpolarization at the negative cellular voltage extremes that follow action potentials, a
reverse of the voltage dependence that characterizes most ion channels. In this manner,
HCN channels provide excitable tissues the unique ability to depolarize
without external influences through sustained positive increases in membrane potential
that are initiated by hyperpolarization and raise the membrane potential to the threshold
for subsequent depolarization. This characteristic contributes to membrane
responsiveness and makes funny current a pacemaker of rhythmic nerve and muscle
firing.
Based upon the inherent ability of increased HCN4 expression in both epithelium
and ASM to alter muscle membrane potentials, we contrasted the contractile responses of
isolated bronchial rings from asthmatic horses and controls in the presence and absence
ivabradine, an HCN4 antagonist. Ivabradine caused a dose dependent right shift in the
percent maximal contraction versus carbachol concentration curve in airways from both
asthmatic and control horses. These results differ from the absence of altered contraction
during HCN inhibition described by McGovern et al. (365) using isolated tracheal strips
from guinea pigs. Several differences in the experimental protocols are noteworthy. First,
there is substantial evidence that contractile responses of trachealis muscle and ASM are
inherently different in both guinea pig and equine asthmatics to account for the differing
behavior observed between the two experiments (42, 366). Next, in the guinea pig
experiments, HCN channel blockers were added 60 minutes before contraction agents. In
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our investigation, the initial ivabradine equilibration was 15 minutes with serial carbachol
concentrations increasing in 15-minute increments. The time of effectiveness with HCN
channel inhibitor treatment should be further investigated. Also, the guinea pig trachealis
strips were pre-incubated with 2 M propranolol and 3 M indomethacin which differs
from our protocol in which the only agents within the tissue bath protocol were
ivabradine and carbachol.
For an in vivo analysis, guinea pigs were anesthetized and mechanically ventilated for
pulmonary inflation pressure (PIP) measurements in response to intravenous histamine.
The HCN4 channel inhibitor ZD7288 caused significant bronchoconstriction. However,
the authors note that their study was done on large airways and could not rule out a
different response in the small airways to HCN channel inhibition.

The proposed

mechanism of this finding centers on an unmasked NK receptor activation of C-fibers in
the airways. However, there are interspecies differences in the ability of tachykinins to
effect trachea and bronchial smooth muscle tone (367, 368). For example, the electrical
field stimulation bronchoconstriction of isolated guinea pig bronchi mediated by
tachykinins is completely reversed in mice and rats (367). In these models, EFS causes a
tachykinin dependent bronchodilation (368). In BDA affected horses, NK-2 receptors are
significantly increased in bronchial epithelium and ASM compared to non-diseased
horses (369). Neurokinin A and B also caused bronchoconstriction in BDA affected
bronchial rings (369). The role of tachykinins has yet to be studied in the EPA variant of
SEA, however. This, coupled with our findings, highlight a future need to study the
effect of ivabradine at the small airways.
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Finally, the guinea pig is an induced model for asthma with a predominance TH2, IgE
mediated eosinophilic inflammation which differs from equine asthma in which
neutrophilic inflammation predominates (22, 340). While these differences could alter the
relevance of HCN4 current to airway contraction, it is noteworthy that HCN4 inhibition
was efficacious in decreasing the contractile responses of bronchi from normal controls,
suggesting that species-specific pharmacodynamic interactions with ivabradine or
inherent species differences in HCN4 current may also be relevant.
The finding that ivabradine decreased contractile responses of both asthmatic and
control bronchi was unanticipated. We hypothesize that this may reflect the fact that only
3 of 7 asthmatic horses were euthanized during the season of disease remission when,
based upon our findings at both the transcript and protein level, HCN4 expression would
be predicted to be decreased in the lung and ASM. Though HCN4 expression in ASM of
horses with pasture asthma that were euthanized during remission was increased relative
to that of non-diseased control horses, we did not identify differences in the ivabradine
mediated decrease in carbachol contractile responses between diseased and control
horses. This suggests that this difference is not physiologically significant in the in vitro
model system that was employed. A challenge to this experimental protocol is the fact
that horses with equine pasture asthma became available for the experimental protocols
reported here through spontaneous donations, the timing of which was not under the
control of the investigators. Similar experimental protocols that contrast ivabradine’s
effect on airway contractility in association with a determination of HCN4 expression in
the airways from larger cohorts during exacerbation and remission are warranted.
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Nonetheless, the primary finding that ivabradine moderated carbachol induced airway
contraction at concentrations that are attained using standard human ivabradine dosing
regimens remains relevant.
We also observed a significant difference in the ivabradine interaction with carbachol
between day 1 and day 2 in our study. We hypothesize that the abundance of day 1
manipulations, which included the actual tissue harvest and bronchial ring dissection,
prolong the tissue’s ability to reach a true equilibrium. Following 24 hours in KrebsHenslett, bronchial rings were more stable in their responsiveness, allowing more
significant interactions to be observed. It is also feasible that following 24 hours of
incubation, medications known to alter muscle contractility that were used for euthanasia
(sodium pentobarbital and xylazine) (370, 371)

had decreased activity through a

combination of diffusion and metabolism during incubation. Interestingly, we have
observed a similar phenomenon in day 1 versus day 2 precision cut lung slices from
horses.
In the heart, the magnitude of funny current resulting from HCN4 channel activation
regulates the slope (duration) of phase 4 diastolic depolarization; determining the
frequency of spontaneous action potential firing of SA myocytes and, therefore heart rate.
The specific HCN4 channel blocker ivabradine, binds to an intracellular site in the
HCN4 channel pore, inhibiting If current, which blunts the diastolic depolarization rate
and decreases heart rate (372). Cyclic nucleotide gating makes HCN channels also
responsive to the autonomic nervous system (350). HCN4 channels, which co-localize
with B2-AR in the heart (373), are slowly gating and strongly sensitive to cAMP.
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Ivabradine has been demonstrated to increase cAMP which would account for the
moderation of airway contraction observed in this investigation. cAMP binds directly to
f-channels and shifts the If activation range to more positive voltages, increasing If
channel open probability. In the heart, this increases the steepness of diastolic
depolarization, shortening its duration and causing heart rate acceleration. Autonomic
regulation of heart rate is accordingly achieved by increases or depletion of cAMP that
result from β-adrenergic or muscarinic M2 receptor stimulation, respectively. Recently,
cyclic dinucleotides have been demonstrated to inhibit HCN4 opening, mimicking the
effects of muscarinic If modulation and providing a mechanism for crosstalk with the
immune system where cNDP signaling is well recognized (374).
Beyond the effects of increasing cAMP, another scenario for the observed
moderation of airway contractile responses in this investigation is that HCN4 mediated If
current raises ASM membrane potential to thresholds that activate other voltage gated ion
channels including voltage gated calcium channels, providing an alternate route of
excitation to the GPCR-IP3-mediated Ca+2 release from SR that predominates in ASM
contraction. Myometrium, which shares this primary contractile pathway with ASM and
has a parallel dependence on intracellular Ca2+ stores for contraction, exhibits changes in
the calcium machinery of the gravid rat uterus to support this hypothesis.
Hyperpolarization-activated inward currents are identified in advancing pregnancy in rat
myometrium (375) and both L-type and T-type voltage gated Ca2+ channels (376) as
well as gap junctions (377) increase in gravid myometrium with advancing gestation. The
resulting current contributes to maintenance of the resting membrane potential and
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spontaneous activity in smooth muscle cells of late pregnant rats (375). If current in ASM
also indicates a mechanistic explanation for the paradoxical ability of β2-AR agonists to
mediate bronchodilation in most asthmatic patients, while simultaneously effecting
bronchoconstriction in more severe asthmatics. Specifically, while β2-AR agonist
mediated increases in cAMP drive ASM relaxation through PKC signaling and
downstream effects on MLC-20, cAMP gating simultaneously increases HCN4 channel
opening, facilitating ASM contraction via a depolarizing shift in the ASM membrane
potential. The outcome of β2-AR signaling would thus reflect the balance between PKC
driven ASM relaxation and HCN4 driven ASM contraction. From this line of evidence
emerges the hypothesis that If modulation may be of value in changing ASM
responsiveness in certain populations of asthmatics.
Overall this work is the first to report the preferential transcription and translation
of HCN4 in association with ASM in a spontaneous asthma model. It is also the first to
demonstrate moderation of ASM contraction via inhibition of HCN4 in an asthma model.
This work highlights the need for further investigations that characterize the effect of
ivabradine on ASM contraction in horses with EPA during disease exacerbation and
remission, as well as the degree of effect at large compared to small airways. Interpreted
with the documented role of HCN4 in regulating membrane excitability, our findings
indicate a role for If current in ASM in asthma and highlight the need to decipher the
roles of HCN4 in bronchial hyper-responsiveness and bronchoconstriction to determine
the therapeutic potential of If modulation in asthma management.

88

A

B

D

E

G

C

F

H

No Age Match

Figure 5

HCN4 protein expression increases in ASM and airway epithelium during
disease in the equine asthma model, and decreases during remission,
maintaining constitutive expression in diseased ASM exceeding that of nondiseased horses.

HCN4 stained lung sections collected during disease exacerbation from three SPARAO
affected horses (panels A-C, ages 7, 16, and 19; respectively), and their respective age
and season matched lung sections from non-diseased control horses (panels D-F),
demonstrate strong HCN4 staining in ASM and to a lesser extent in the apical regions of
epithelial cells during disease. In panels G-H HCN4 stained lung sections collected
during disease remission (ages 12 and 17 respectively) identify constitutive HCN4
staining in ASM that is less than observed during disease exacerbation (Panels A-C) but
exceeds non-diseased controls. HCN4 staining is no longer evident in airway epithelium
during disease remission. No comparable remission age match was available for the first
column.
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Figure 6

Ivabradine decreases bronchial hyper-responsiveness to carbachol mediated
contraction.

The ability of ivabradine (1μM), ivabradine (3μM), ivabradine (5μM), ivabradine
(10μM), to moderate carbachol induced contractile responses was evaluated using two
ivabradine treated and two nontreated control bronchi isolated from 17 horses. Results
are graphed as the average percentage of maximal contraction of 17 horses. Error bars
represent SEM. * are significantly different on day 1, and ^ are significant on day 2 (p <
0.05).
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Table 5

P-values for bronchial rings treated vs. untreated with ivabradine

Day 1
Day 2
Ivabradine 1uM
3uM
5uM
10 uM
1uM
3uM
5uM
10
dose
uM
0.9997
0.9980
1.0000
0.9999
1.0000
0.9982
0.9998
0.9991
0.1 nM
CC
0.9887
1.0000
1.0000
1.0000
0.9712
0.9885
0.9914
1 nM CC 0.9998
0.9976
0.9159
1.0000
1.0000
0.7379
0.8994
1.0000
1.0000
3.3nM CC
0.5314
0.7560
1.0000
1.0000
0.0328*
0.0200*
0.1741
0.9992
10nM
0.2425
0.9571
0.9962
1.0000
0.3209
0.1004
0.0148*
1.0000
33nM
0.0058*
0.4161
0.0640
0.9695
0.0126*
<.0001*
<.0001*
0.8539
100nM
0.0102*
0.8612
0.0040*
0.1307
0.1234
<.0001*
<.0001*
0.0982
330nM
0.0287*
0.9962
0.0045*
0.0044*
0.1961
0.0008*
<.0001*
0.0117*
1uM
0.8545
1.0000
0.0102*
0.0006*
0.9999
0.0530
0.0024*
0.0854
3.3uM
0.8808
1.0000
0.9999
0.9967
0.4873
0.0055*
0.6234
10uM
n/a
1.0000
1.0000
0.8608
0.0159*
1.0000
0.6411
0.4217
0.7158
33uM
Notes: * indicates significant p-value (<0.05). n/a=comparison unable to be made
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CHAPTER IV
SUMMARY

The overarching goal of this research is to substantiate the clinical relevance of equine
pasture asthma (EPA) to severe adult human asthma as a foundation for employing EPA
as an asthma model capable of identifying novel mediators of airway hyperresponsiveness. From a position of improved relevance as an asthma model, it is reasoned
that mediators identified in EPA horses would have an increased likelihood of relevance
to severe human asthma. This is necessary because discoveries made in the most
commonly employed animal asthma model, the mouse, demonstrate less than an 85%
success of translation (240, 241). In addition, asthma models that employ mice, rats,
guinea pigs as well as larger animal models including sheep and non-human primates
require sensitization with an antigen to develop the asthma phenotype (247,250,251, 265,
271,273, 278, 300, 302, 307, 308). The disease that develops in these models differs
substantially from human asthma in that these models eventually develop tolerance after
repeated challenge with the sensitizing antigen (334), require higher doses of airway
spasmogens than human asthmatics to achieve clinically significant airway hyperresponsiveness (247,250,265), and develop inflammatory cell types (eosinophils) that
only model half of the population of human asthmatics (265,300, 334). Therefore, EPA
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was chosen for scrutiny in this dissertation as a model for severe human asthma because
it fills the aforementioned voids of other animal asthma models, being not only a
naturally occurring asthma disease of horses that therefore does not require initial
sensitization (8,9,10), but also an asthma condition which persists for the life of the horse
(7,8) effectively substantiating that tolerance to the inciting triggers does not occur.
Finally, EPA was pursued for further investigation because of its documented
neutrophilic airway inflammation (8,22) which is a characteristic of not only more than
50% of the adult asthmatic population (149), but also of severe and corticosteroid
resistant human asthmatics which constitute the most difficult and costly asthmatics to
treat (155,347).
My first hypothesis predicted that EPA affected horses would possess a critical facet
of severe asthma that is not well addressed in other animal asthma models, specifically
the presence of airway hyper-responsiveness (AHR) that is persistent and of a magnitude
that mirrors AHR in severe human asthmatics. Induced asthma models are limited as
translational models because the magnitude of their AHR is much lower than human
asthmatics and is not persistent, meaning that the AHR abates following cessation of
exposure to the sensitizing antigens used to induce an asthma phenotype (247, 263, 334).
To this end methacholine bronchoprovocation was performed using a threshold
established for noncompliant humans who are unable to mount forced expiratory
maneuvers that are typically used in bronchoprovocation protocols that quantify AHR in
human asthma. Bronchoprovocation of EPA horses employing this threshold (the
concentration of methacholine that caused a 40% increase in lung resistance) identified
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methacholine concentrations to achieve the threshold that are employed by the American
Thoracic Society to diagnose moderate to severe human asthma (79). Further, the
magnitude of the AHR identified in 5 EPA horses was identical or within one doubling
dose of methacholine when re-evaluated between 3 and 34 months following the initial
methacholine bronchoprovocation, confirming persistent AHR. In addition, non-diseased
control horses failed to react to methacholine thresholds that similarly rule out asthma in
humans.
Finally, to further substantiate the model, reversibility of airway obstruction, also a
key diagnostic feature of human asthma, was documented in 8 horses that were
experiencing clinical disease and were treated with the β2-adrenergic agonist levalbuterol.
Together with the previously mentioned chronic neutrophilic airway inflammation, these
findings substantiate the critical components of clinical asthma diagnosis namely,
reversible airway obstruction and in particular the persistent AHR (2,109) that is not well
modeled in other animal asthma models (334). This latter feature has similarly not been
demonstrated in the Severe Equine Asthma variant of Barn Dust Asthma for longer than
3 days (89).
From the vantage of proven clinical relevance of EPA to the severe human asthma
phenotype, and particularly given the model’s unique ability to model persistent AHR of
a magnitude that is diagnostic of severe human asthma, we hypothesized that mediators
of AHR identified in EPA horses would have improved relevance to the human
condition. Employing RNA sequencing of serial lung biopsies from EPA affected horses
and clinically normal controls, HCN4 was identified as differentially expressed at the
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transcript level in EPA affected horses during seasonal exacerbation. HCN4 was
prioritized for further investigation because of its known role in increasing resting muscle
membrane potentials to thresholds that trigger voltage gated calcium channels (350, 356).
It was reasoned that such activity in airway smooth muscle could lead to irritability and
alter contractile functions. HCN4 expression was not identified in the transcriptomes of
non-diseased control horses, nor in the transcriptomes of EPA horses during disease
remission. These findings were confirmed at the protein level using
immunohistochemical staining which revealed increased HCN4 protein in the airway
smooth muscle of EPA affected horses that were euthanized during disease exacerbation,
relative to EPA affected horses that were euthanized during disease remission in which a
low level of constitutive HCN4 expression was identified in airway smooth muscle.
Congruent with the transcriptome findings, HCN4 protein was not identified in the
airway smooth muscle of control horses.
Based upon the hypothesis that HCN4 mediated current contributes to airway
contraction, the ability of ivabradine (a specific HCN4 inhibitor (356)) to moderate
bronchial contraction in the horse was evaluated. In these experiments, bronchial rings
bathed in ivabradine concentrations known to be achieved with labeled human dosing (110uM) demonstrated a dose dependent right shift of the % maximal contraction versus
carbachol concentration curve. Accordingly, these results substantiate that HCN4
mediated current contributes to the generation of airway contractile forces. At the time of
this discovery, HCN4 had yet to be characterized in the lung. Though the Gene
Expression Omnibus contains entries relevant to the expression of HCN4 in human lung
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transcriptomes, these entries do not identify differences in association with asthma.
However, it is critical to recognize that each of the GEO entries fail to examine the
changes in HCN4 in individual asthmatics during disease exacerbation and remission.
This timing in our approach was critical to our discovery because HCN4 increases in
association with disease exacerbation and decreases in association with disease
remission. In addition, the human asthmatic populations represented within the GEO
database are much more heterogenous with respect to disease severity and treatment
effects then were horses in this investigation. It is noteworthy however that ivabradine
decreased airway responsiveness in normal bronchi, indicating efficacy that is likely to
not be dependent on the magnitude of HCN4 expression. Beyond GEO, only one other
study has investigated the effect of HCN4 mediated current on airway contractility in
another animal asthma model.
Despite the evidence presented herein that HCN4 current contributes to airway
contraction, further characterization of the role of HCN4 in AHR is needed. A major
challenge to this work is the inability to predict the ultimate relevance of HCN4 to airway
contraction in humans with asthma. One next step would be to examine HCN4 expression
in bronchial biopsy samples from a well-controlled cohort of severe asthmatics that
possess neutrophilic airway inflammation. However, a series of investigations remain
indicated in the horse including determining the role of HCN4 in asthma exacerbation
versus remission, the role of HCN4 at small airways in the equine lung, as well as in vivo
investigations of HCN4 blockade in lessening AHR.
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To investigate the expression of HCN4 in affected horses while in clinical season, my
lab will continue to analyze ivabradine effects on carbachol induced bronchial
contractions in vitro from horses euthanized in EPA exacerbation. HCN4 expression will
also be quantified using qPCR from these bronchial rings in order to associate the
contractile responses of bronchial rings treated with ivabradine to the magnitude of
HCN4 expression. From the differential protein expression already identified in the
airway smooth muscle of EPA affected horses in exacerbation compared to controls and
EPA affected horses in remission, I hypothesize that HCN4 expression will be increased
in reactions run from bronchial rings of EPA horses euthanized in exacerbation.
However, given that ivabradine reduced bronchial contractions in both EPA affected and
normal control horses, I expect there to be some level of expression in control horses.
Our lab has recently begun investigating the potential of ivabradine to reduce airway
contraction at the small airways. A similar tissue bath experiment as that used in chapter
three will be used for this investigation. We hypothesize that a similar reduction in
bronchial contraction in ivabradine treated rings will be observed in the smaller airways,
expanding the differences observed in our equine model of asthma relative to the guinea
pig experiment in which HCN4 blockade increased the contractile responses of trachealis
muscle discussed in chapter 3.
Finally, our lab aspires to investigate the in vivo effect of ivabradine on EPA affected
horses. To accomplish this, a pharmacokinetic study will need to be done to determine
the dose of ivabradine needed to reach the therapeutic levels achievable in humans and
used in chapter 3 of this study (1-10uM ivabradine). Once doses are established, we
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hypothesize that ivabradine can be used as a drug to reduce AHR. Therefore, we propose
to perform methacholine challenges similar to those performed in chapter two prior to
and following treatment with ivabradine to determine the effect of HCN4 blockade on
moderating airway hyper-responsiveness. We hypothesize that horses treated with
ivabradine will reach study PC40RL at higher methacholine concentrations than those
untreated, proving reduced airway hyper-reactivity.
In conclusion, this dissertation research has proven equine pasture asthma to be
diagnostically similar to severe human asthma and has demonstrated the utility of the
model in its elucidation of novel gene targets that mediate airway contraction. It is this
author’s hope that the role of HCN4 antagonism in asthma will one day be
pharmacologically relevant in treatment of both equine and human asthma.
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